Name of journal:  *World Journal of Transplantation*

ESPS Manuscript NO: 9346

Columns: REVIEW

**Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies**

Mathis AS *et al.* Late calcineurin inhibitor sparing: Kidney transplantation

Andrew Scott Mathis, Gwen Egloff, Hoytin Lee Ghin

**Andrew Scott Mathis,** Pharmacy Department, Monmouth Medical Center, Long Branch, NJ 07740, United States

**Gwen Egloff,** University of Connecticut, School of Pharmacy, Storrs, CT 06268, United States

**Hoytin Lee Ghin,** Pharmacy Department, Monmouth Medical Center, Long Branch, NJ 07740, United States

**Author contributions:** All authors have made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published.

**Correspondence to: Andrew Scott Mathis, RPh, BS, PhD,** Pharmacy Department, Monmouth Medical Center, 300 Second Avenue, Long Branch, NJ 07740, United States. [smathis@barnabashealth.org](mailto:smathis@barnabashealth.org)

**Telephone:** +1-732-9236753 **Fax:** +1-732-9236757

**Received:** February 8, 2014 **Revised:** March 24, 2014

**Accepted:** May 14, 2014

**Published online:**

**Abstract**

Kidney transplantation improves quality of life and reduces the risk of mortality. A majority of the success of kidney transplantation is attributable to the calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, and their ability to reduce acute rejection rates. However, long-term graft survival rates have not improved over time, and although controversial, evidence does suggest a role of chronic CNI toxicity in this failure to improve outcomes. Consequently, there is interest in reducing or removing CNIs from immunosuppressive regimens in an attempt to improve outcomes. Several strategies exist to spare calcineurin inhibitors, including use of agents such as mycophenolate mofetil (MMF), mycophenolate sodium (MPS), sirolimus, everolimus or belatacept to facilitate late calcineurin inhibitor withdrawal, beyond 6 mo post-transplant; or using these agents to plan early withdrawal within 6 mo; or to avoid the CNIs all together using CNI-free regimens. Although numerous reviews have been written on this topic, practice varies significantly between centers. This review organizes the data based on patient characteristics (*i.e.*, the baseline immunosuppressive regimen) as a means to aid the practicing clinician in caring for their patients, by matching up their situation with the relevant literature. The current review, the first in a series of two, examines the potential of immunosuppressive agents to facilitate late CNI withdrawal beyond 6 mo post-transplant, and has demonstrated that the stongest evidence resides with MMF/MPS. MMF or MPS can be successfully introduced/maintained to facilitate late CNI withdrawal and improve renal function in the setting of graft deterioration, albeit with an increased risk of acute rejection and infection. Additional benefits may include improved blood pressure, lipid profile and serum glucose.Sirolimus has less data directly comparing CNI withdrawal to an active CNI-containing regimen, but modest improvement in short-term renal function is possible, with an increased risk of proteinuria, especially in the setting of baseline renal dysfunction and/or proteinuria. Renal outcomes may be improved when sirolimus is used in combination with MMF. Although data with everolimus is less robust, results appear similar to those observed with sirolimus.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Kidney transplantation; Calcineurin inhibitor; Withdrawal; Sparing; Cyclosporine; Tacrolimus; Renal function; Graft survival

**Core tip:** Mycophenolic acid derivatives have been used successfully to facilitate late CNI withdrawal to improve short-term renal function in kidney transplantation. The benefit carries an increased risk of acute cellular rejection. Sirolimus and everolimus are also options, but have comparatively less evidence and carry and increased risk of proteinuria, which is dependent on baseline renal function.

Mathis AS, Egloff G, Egloff HL. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. *World J Transplant* 2014; In press

**INTRODUCTION**

Compared with hemodialysis, kidney transplantation improves quality of life and reduces of mortality risk[1-3]. The survival benefit of kidney transplantation over hemodialysis applies even to the use of marginal donor kidneys[4]. Much of this success has been attributed to calcineurin inhibitors, cyclosporine and tacrolimus, and their ability to reduce acute rejection rates. However, despite dramatic reductions in acute rejection rates over time, long-term graft survival rates have not improved to an appreciable extent[5,6]. A number of factors have been postulated that contribute to the lack of improvement in graft survival, including donor factors, recipient factors, human leukocyte antigen (HLA) matching, death with a functioning allograft, delayed graft function, calcineurin inhibitor toxicity, chronic allograft nephropathy, and infectious nephropathy (BK virus)[6].

Calcineurin inhibitor nephrotoxicity was recognized early after the use of cyclosporine began, and it comes in many forms[7]. Calcineurin inhibitors cause acute and chronic nephrotoxicity. The acute forms include arteriolopathy, tubular vacuolization and thrombotic microangiopathy. Chronic forms of nephrotoxicity include interstitial fibrosis and tubular atrophy, medial arteriolar hyalinosis, glomerular capsular fibrosis, global glomerulosclerosis, focal segmental glomerulosclerosis, juxtaglomerular apparatus hyperplasia, and tubular microcalcifications, many of which can be caused by other factors and tend to be nonspecific findings on post-transplant biopsy[7]. Because of the known contribution of calcineurin inhibitors to nephrotoxicity, there has been much interest in finding the optimal agent and/or regimen[8-14]. While many studies demonstrated improved renal function with reduced dose calcineurin inhibitor use, or an early benefit on renal function with tacrolimus use when compared to cyclosporine, improvements in long-term graft function were not demonstrated[9-14]. Additionally, there are numerous differences in the adverse event profile of cyclosporine and tacrolimus. Many outside factors differentiate the calcineurin inhibitors and influence their contribution to nephrotoxicity, including therapeutic drug monitoring strategy, dosing strategy, drug-drug interaction, pharmacogenetics, and non-adherence[15-20]. These medication-related variables make nephrotoxicity and decline in allograft function very difficult to predict in practice. The lack of surveillance biopsies also makes differentiation of outcomes related to calcineurin inhibitor use and non-medication related factors difficult in practice[21-25].

A long-term biopsy study helped determine the true consequence of calcineurin inhibitors on chronic allograft nephropathy and graft failure[26]. In a well-designed study, Nankivell *et al*[26] demonstrated the natural history of chronic allograft nephropathy in 120 type 1 diabetics who underwent kidney-pancreas transplant followed by routine biopsies over a 10 year period. The initial phase (year 1) in the development of chronic allograft nephropathy was characterized by early tubulointerstitial damage from ischemic injury, prior severe rejection, and subclinical rejection, where these findings were present in 94.2% of patients. Beyond year 1, chronic allograft nephropathy was characterized by microvascular and glomerular injury and chronic rejection, defined as subclinical rejection for two or more years, and was uncommon (5.8%). Progressive high-grade arteriolar hyalinosis with luminal narrowing, increasing glomerulosclerosis, and tubulointerstitial damage were linked to the calcineurin inhibitors, and were irreversible. Despite dose reductions of both cyclosporine and tacrolimus, calcineurin inhibitor nephrotoxicity was nearly universal by 10 years, and was found to be the chief cause of late injury and renal function decline[26].

The data from Nankivell *et al*[26] suggested that chronic allograft nephropathy was primarily a function of calcineurin inhibitor nephrotoxicity. This has been interpreted with controversy, but the data surrounding the definition and pathophysiology of chronic allograft nephropathy have always been controversial, due to varied definitions utilized in both practice and research[27,28]. In addition, many believe that calcineurin inhibitor nephrotoxicity is a non-specific finding[7,22]. Still, the evidence from Nankivell[26] is the among the most robust long-term evidence available on calcineurin inhibitors. It should also be mentioned that objective assessment is superior to clinical assessment, to determine the presence of chronic allograft nephropathy and calcineurin inhibitor nephrotoxicity, because clinicians underestimate the chronic renal toxicity[29,30]. Despite underestimation, clinicians have many ways of dealing with perceived medication toxicity. Commonly, when adverse effects are noted, adjustments are made in the regimen of the individual patient[31]. This may result in unintended consequences, such as acute rejection and graft loss[32-34].

Collectively, protocols have been developed to assess the conversion between calcineurin inhibitors, or to select a preferable one, in order to avoid certain toxicities, or promote renal function improvements or short-term graft survival[9-14,35]. However, in a paired kidney analysis from a database with 5-year follow-up, no difference could be determined between cyclosporine and tacrolimus with respect to allograft survival, despite superior renal function in the tacrolimus group[36]. These results were similar in a prospective study with mean 2.8 years follow-up, and supported a 5-year histologic study that determined similar development of moderate to severe arteriolar hyalinosis with cyclosporine or tacrolimus[37,38]. When patients are switched between the two calcineurin inhibitors, or one is used in preference to the other, the basic tenet that calcineurin inhibitors are the primary contributors to graft decline is ignored[30]. In addition, the graft decline appears to occur primarily between 5 and 10 years post transplant[26]. It must also be emphasized that switching agents off-protocol in an uncontrolled way may have harmful effects, and is inconsistent with evidence-based practice[32].

In recent years, various schools of thought have emerged with the introduction of newer agents and experience gained through research. The main strategies are based on personalization, corticosteroid minimization, and calcineurin inhibitor sparing[39,40]. It is too soon for personalized medicine, although the foundation has been laid[17-19,39]. Steroid avoidance strategies have been generally disappointing. They focus on minimizing adverse effects, and usually require calcineurin inhibitor persistence for successful outcome[40-47]. Calcineurin inhibitor sparing strategies also aim to reduce adverse effects, but also seek to improve graft survival[43-66].Understanding the different treatment options may lead to improvement in long-term care.

Although the calcineurin inhibitor sparing strategies have been extensively reviewed, we aim to provide a unique approach to the issue. Since many transplant centers have set protocols for their specific populations, and clinical trial results or experiences of other centers may not be generalizable, we aim to review the literature according to general age groups (adult and pediatric) and therapeutic approaches (de novo, early or late) based on the specific baseline regimens used. We will analyze calcineurin inhibitor withdrawal and avoidance, and only touch on minimization when directly compared since exposure appears to lead to chronic toxicity and follow-up was usually inadequate to determine the true consequence on chronic allograft nephropathy[26,54].

Due to the expanse of the issue, we will divide the topic into two manuscripts. The first, herein, will cover late calcineurin inhibitor withdrawal, beyond 6 mo post-transplant, and the second will cover early withdrawal and de novo avoidance. We will focus primarily on renal function and graft survival as the main outcomes of interest, and make recommendations based on the available evidence for each clinical subgroup since data on predicting or monitoring the outcome of changes in immunsuppression are still lacking[67-78].The intent of the article is to aid the practicing clinician in identifying studies relevant to their practice to assist in clinical decision making. The clinician may have to refer the cited articles to find more specific information, such as the countries where the analysis was performed, ethnic breakdown of the population, transplant characteristics, etc.

**STRATEGIES**

Three basic strategies are available for calcineurin-sparing, “Avoidance”, and “Early” and “Late” reduction or withdrawal. Late, defined as calcineurin inhibitor reduction withdrawal or elimination beyond 6 mo (> 6 mo) after the kidney transplant, is a strategy that has been frequently used when patients are faced with diminishing renal function, possibly related to established toxicity, and is the focus of this manuscript. Early, defined as calcineurin inhibitor withdrawal or reduction within the first 6 mo (≤ 6 mo) after the kidney transplant, is generally done to prevent anticipated calcineurin inhibitor toxicity or in response to early evidence of diminished renal function. Calcineurin inhibitor avoidance or calcineurin inhibitor-free regimens are typically a proactive strategy in response to the concerns about the potential toxicity of the calcineurin inhibitors and their failure to promote long-term graft survival, despite dramatic reduction in the risk of acute cellular rejection. Early and de novo are the focus of a second manuscript in this series.

Our search strategy involved PubMed database for all years until August 2013 for articles involving kidney or renal transplantation with the search terms calcineurin inhibitor “reduction”, “withdrawal”, “elimination”, “avoidance”, “minimization”, “sparing”, and “free”. References of identified articles were reviewed to identify additional articles of interest. Articles were separated according to the post-transplant time period when the intervention took place, according to the three categories (avoidance, early, and late), and then arranged according to population and baseline regimen. Based on the assumption that most long-term calcineurin inhibitor nephrotoxicity is irreversible and progressive, and minimization articles were only included if they directly compared with avoidance or withdrawal/elimination regimens. The remainder of the article will summarize the available evidence by patient type, intervention and baseline regimen .

**ADULT PATIENTS AT VARIABLE TIME POST-TRANSPLANT**

***Regimens utilizing older agents to eliminate calcineurin inhibitors***

**Baseline calcineurin inhibitor and corticosteroid with or without azathioprine:** A meta-analysis by Kasiske *et al*[79] evaluated early studies of calcineurin inhibitor withdrawal in patients on a baseline regimen of azathioprine, cyclosporine and corticosteroid, and compared calcineurin inhibitor withdrawal with continuation (part 1), and calcineurin inhibitor withdrawal with patients who never received calcineurin inhibition (part 2)[79]. In part 1 of the meta-analysis, 17 studies were included, with 9 of them including patients withdrawn during the first 6 mo after the transplant. The mean duration of follow-up of the studies was 26.6 ± 7.5 mo. It should be noted that the meta-analysis included mixed populations, containing patients withdrawn due to toxicity of cyclosporine (3 studies), patients with stable renal function and/or without recent rejection (10 studies), recipients of living donor kidneys (6 studies), and patients with first transplant (4 studies). In part 1, there was a higher rate of acute rejection episodes per patient in the cyclosporine withdrawal group [0.126; 95% confidence interval (CI), 0.085 to 0.167; *P* < 0.001], but no difference in graft loss per patient per year (-0.009; 95%CI: -0.022 to 0.004, *P* = 0.19) or deaths per patient per year (-0.005; 95%CI: -0.016 to 0.006, *P* = 0.4). The authors noted a trend toward higher serum creatinine in the control group who continued cyclosporine relative to those who discontinued the agent (1.84 ± 0.29 *vs* 1.63 ± 0.28 mg/dL; *P* = 0.17). In part 2 of the meta-analysis, consisting of 6 studies, 3 included stable patients, none involved withdrawal due to toxicity, 3 studies included living donor kidneys, and 2 studies included only the first allograft, and 5 were performed in the first 6 mo after the transplant. The mean duration of follow-up was 28.8 ± 11.6 mo. When the six studies were analyzed together, the rate of graft loss per patient per years was similar (-0.02; 95%CI: -0.022 to 0.003, *P* = 0.08), but when only the 3 randomized trials were considered, graft survival was better among those withdrawn from cyclosporine (0.0382; 95%CI: 0.0002 to 0.0762, *P* = 0.049). The deaths per patient per year were similar (0.001; 95%CI: -0.006 to 0.008, *P* = 0.87) and the serum creatinine was nonsignificantly higher in the group who never received calcineurin inhibitors (1.71 ± 0.36 *vs* 1.50 ± 0.18 mg/dL; *P* = 0.2). The authors noted that none of the outcomes were affected by the timing (before or after 6 mo) or method (slow or rapid taper) of cyclosporine withdrawal[79].

This meta-analysis demonstrated that cyclosporine withdrawal resulted in an early increase in the risk of acute cellular rejection, but similar graft function, graft survival and patient survival at about 2 year follow-up to patients retained on cyclosporine or who never received cyclosporine[79]. Despite promising results, azathioprine as an antiproliferative has been largely replaced in practice with newer agents that are considered more potent immunosuppressants. Another study evaluated withdrawal of cyclosporine using azathioprine versus mycophenolate mofetil in patients 1 year post-transplant. The primary endpoint was development of donor-specific antibodies (DSAs), measured by complement-dependent cytotoxicity assay, enzyme-linked immunosorbent assay (ELISA) and flow-cytometry crossmatch with donor spleen cells. DSAs, by three methods were not detected during cyclosporine treatment or during acute rejection treatment while on cyclosporine, but after conversion to azathioprine, 3 of 8 (37.5%) had DSAs in the presence of acute rejection, while none (0 of 6) of the mycophenolate mofetil patients had DSAs during rejection. These results highlight the potential benefits of mycophenolic acid over azathioprine, which have been described previously[80-82].

**ADULT PATIENTS 6 OR MORE MONTHS POST-TRANSPLANT**

***Regimens utilizing mycophenolic acid to eliminate calcineurin inhibitors***

**Baseline calcineurin inhibitor and corticosteroid:** At least two studies[83,84] evaluated patients withdrawn late from a calcineurin inhibitor with a baseline regimen of calcineurin inhibitor and corticosteroid (Table 1)[83-93]. One study was designed to prospectively evaluate arterial distensibility and endothelial function before and after removal of cyclosporine in a population with biopsy-proven CAN and deteriorating renal function. MMF was introduced at 500mg per day and increased to a target dose of 2000 mg per day over 4 wk. The mean daily dose of MMF was 1700 mg at the end of the trial. Half the patients were randomized to withdrawal (tapered to off over 4 wk) and half to cyclosporine continuation. At 6 mo, serum creatinine increased slightly in both groups, but to a numerically greater extent on the control group who remained on cyclosporine. Though blood pressure improved from baseline in the intervention group, but not in the control group, there was no significant effect on brachial artery endothelial-dependent vasodilation. Acute rejection was not reported[83]. Another study performed by the same investigators also evaluated patients with biopsy-proven CAN, serum creatinine less than 4 mg/dL, and deteriorating renal function. That study introduced MMF more aggressively, at 1 g/d, and titrated to 2 g/d over 3 wk, and then patients were randomized to withdrawal or continuation of the calcineurin inhibitor. In patients randomized to withdrawal, the calcineurin inhibitor was reduced by 33% every 2 wk. The primary endpoint of slope of reciprocal serum creatinine per month at week 35 was positive and higher (0.00585 ± 0.01122) in the dual therapy group than the triple therapy group (-0.00728 ± 0.01105). Additional findings were the degree of proteinuria (*P* = 0.01), diastolic blood pressure (*P* = 0.04) and mean arterial pressure (*P* = 0.04), which were lower in the dual therapy group at follow-up. No episodes of acute rejection were reported[84]. These results provide modest evidence that late withdrawal of calcineurin inhibitor with replacement by MMF may improve renal function, or at least reduce the rate of deterioration of renal function, and improve blood pressure relative to calcineurin inhibitor continuation.

**Baseline calcineurin inhibitor, corticosteroid and azathioprine:** A prospective, single-center randomized trial randomized patients on cyclosporine, azathioprine and corticosteroid, with biopsy-proven CAN and deteriorating renal function to MMF or tacrolimus. In patients randomized to cyclosporine, it was discontinued 24 h before tacrolimus was initiated. In patients randomized to MMF, MMF was introduced at 500 mg twice daily and then titrated up over 2-4 wk to 2 g/d. After 6 wk, cyclosporine was incrementally reduced to achieve withdrawal by 14 wk. Azathioprine was discontinued at conversion. At 6-mo, measured glomerular filtration rate (GFR) and serum creatinine were not improved in the tacrolimus group, but in the MMF group, GFR (< 0.001) and serum creatinine (*P* < 0.001) were improved. In contrast, total cholesterol and triglycerides improved from baseline in the tacrolimus group, but not in the MMF group, and systolic and diastolic blood pressure improved in the MMF group, but not the tacrolimus. There were no reported rejection episodes[85]. Another study evaluated consecutive patients converted from cyclosporine, azathioprine and corticosteroid to MMF plus corticosteroid for CAN. Azathioprine was immediately stopped and MMF was introduced over 1 wk, with target dose of 1500 to 2000 mg per day. Calcineurin inhibitor was withdrawn over 4 wk by 25% reduction. Estimated GFR improved from the time of conversion to 1-year follow-up by 2 mL/min, but the authors cautioned that there was a dramatic increase in the risk of infection in the patients converted to MMF[86].

**Baseline calcineurin inhibitor monotherapy, calcineurin inhibitor with corticosteroid, calcineurin inhibitor with azathioprine, or calcineurin inhibitor, corticosteroid and azathioprine:** The “Creeping Creatinine” study[87] evaluated patients on various calcineurin inhibitor-based regimen who did not receive MMF at baseline. In the open, randomized, multicentered trial, patients had a negative slope of reciprocal serum creatinine, baseline serum creatinine of 100 to 400 μmol/L and a calculated creatinine clearance of at least 20 mL/min. A biopsy had to show absence of transplant glomerulopathy, recurrent renal disease, de novo renal disease, obstruction, renal artery stenosis, acute rejection, or acute rejection within 3 mo. Patients were randomized to MMF or maintenance of cyclosporine according to normal practice. Those randomized to MMF had the drug introduced incrementally over 4 wk to a target dose of 2g/d, and corticosteroids were introduced if not previously used. Cyclosporine was reduced in three steps over 6 wk to off. Patients randomized to maintain cyclosporine were continued as per usual practice with a permitted reduction of cyclosporine to a trough not less than 80 ng/mL. Baseline biopsies documented CAN in 78% of the MMF group and 77% of the cyclosporine group. A responder, defined as an improvement in the slope of 1/SCr with no change in the randomized treatment and no graft loss occurred in 58% of the MMF group and 32% of the control group (*P* = 0.006) at 6 mo and 48% of the MMF group and 35% of the control group (*P* = 0.1185) at 1 year. At 12-mo the least squares mean (LSM) creatinine clearance was +5 mL/min in the MMF group and -0.7 mL/min in the cyclosporine group (*P* < 0.01). LSM serum creatinine and serum cholesterol were lower in the MMF group at follow-up, and platelet count was higher, but triglycerides, hemoglobin, white blood cell count, systolic blood pressure and diastolic blood pressure were not significantly different. There were no acute rejection episodes in either group. The incidence of diarrhea, abdominal pain and opportunistic infections were numerically higher in the MMF group[87].

**Baseline calcineurin inhibitor and corticosteroid with or without azathioprine or MMF:** A study evaluated patients on calcineurin inhibitor and corticosteroid, with or without azathioprine or MMF, in a prospective non-randomized, single-centered fashion where decision to reduce or withdrawal CNI was arbitrary[88]. Patients with deteriorating renal function and CAN on biopsy were started on MMF (target 2g/d) if it was not previously given, and azathioprine was stopped. Patients were analyzed in three groups, those who had CNI withdrawn (*n* = 18), those with a 50% reduction in cyclosporine after MMF introduction (*n* = 67), and those with 50% reduction in tacrolimus after MMF was introduced (*n* = 33). At mean 651 d follow-up, 91.7% of the withdrawal group, 51.7% of the reduced dose cyclosporine group, and 59.3% of the reduced dose tacrolimus group had improved or lack of deterioration in the LS 1/SCr (*P* = 0.038). The withdrawal group also had lower serum glucose (*P* < 0.05) and total cholesterol (*P* < 0.05), but not systolic or diastolic blood pressure. It should be noted that patients selected for CNI withdrawal had a lower incidence of acute rejection prior to the intervention, but the nadir serum creatinine was similar in all three groups[88]. A continuation of the trial, out to 76 mo demonstrated that about one third of the CNI reduction patients and only 7.7% of the withdrawal group lost their graft during follow-up (*P* = 0.05). The serum creatinine at follow-up was 2.7 mg/dL in the withdrawal group and 3 mg/dL in the CNI reduction groups[89]. A randomized, controlled, multicenter trial also evaluated patients on cyclosporine and corticosteroid, with or without azathioprine or MMF. Patients were selected if they had a first or second cadaveric or living transplant, were between 12-30 mo post-transplant and maintained on a cyclosporine-based regimen. Patients had to have had no more than one acute rejection episode, with none in the last 3 mo, and a SCr less than 300 μmol/L for at least 3 mo. All patients had MMF introduced to a target of 2 g/d over 3 mo. Patients randomized to cyclosporine withdrawal had it tapered over 3 mo (*n* = 85) and those randomized to remain on cyclosporine (*n* = 85), continued on triple-drug therapy. Creatinine clearance improved by 10% in 46% of the withdrawal group, and the creatinine clearance difference was 4.5 mL/min higher in the withdrawal group 9 mo after randomization (*P* = 0.16). Serum creatinine improved by decreasing 1 μmol/L in the withdrawal group, and increased 4 μmol/L in the continuation group, creating a net effect of 5 μmol/L in favor of the withdrawal group (*P* = 0.34). Withdrawal improved the total (*P* = 0.02) and LDL cholesterol (*P* = 0.015), but blood pressure did not differ significantly. Acute rejection (10.6% *vs* 2.4%; *P* = 0.03) and diarrhea were more common in the withdrawal group[90]. A five-year follow-up publication demonstrated a creatinine clearance of 67.4 mL/min in the withdrawal group and 61.7 mL/min (*P* = 0.05) in the continuation group, but graft loss due to chronic rejection occurred in 12% of the withdrawal group and 8% of the continuation group, due to a respective acute rejection rate of 10% and 1% (*P* = 0.028) [91].

**Baseline calcineurin inhibitor with or without corticosteroid and with or without MMF or MPS:** One retrospective study analyzed 17 patients approximately 11 years post-transplant for 4 years before and after conversion to MPS for biopsy-proven CNI toxicity (*n* = 7) or clinical deterioration of GFR and exclusion for other reasons for graft dysfunction. Patients on CNI and corticosteroid were converted to MPS and prednisolone, patients on CNI monotherapy were converted to MPS alone, and patients on triple therapy were converted to MPS with prednisolone. At conversion, GFR was 43 ± 15 mL/min. After conversion, graft function, as determined by GFR, improved within one month, and peaked at 55.7 ± 21.7 mL/min at one year (*P* = 0.00362), but then declined to near-baseline (44 ± 27 mL/min; *P* = 0.91) by four years, indicating a slowing of progression. However, the overall slope of the regression line for GFR did not change significantly (*P* = 0.116). Three patients discontinued MPS due to infection (*n* = 2) and lost to follow-up (*n* = 1)[92]. A randomized trial compared CNI withdrawal (*n* = 79) with MMF withdrawal (*n* = 79) in patients who were on CNI/MMF/corticosteroid triple therapy. This trial used concentration controlled area-under-the-curve (AUC) monitoring for the CNIs (3250 ng/mL per hour for cyclosporine, 120 ng/mL per hour for tacrolimus) and MMF (75 μg/mL per hour). Estimated GFR was significantly better in the CNI withdrawal group at 6 wk (63.1 ± 1.9 mL/min *vs* 55.2 ± 1.9 mL/min; *P* = 0.004), 1-year (61.1 ± 1.8 mL/min *vs* 52.9 ± 1.8 mL/min; *P* = 0.002), and 3-year (59.5 ± 2.1 mL/min *vs* 51.1 ± 2.1 mL/min; *P* = 0.006). By 6 mo, 1.3% of the MMF withdrawal group and 3.8% of the CNI withdrawal group had biopsy-proven acute rejection. None were high immunologic risk. Three year graft survival did not differ. Blood pressure, lipid values, proteinuria and infections did not differ between the groups. Anemia was more frequent in the CNI withdrawal group[93].

**Summary of MMF and MPA studies:** These studies suggest that MMF or MPS can be introduced or maintained to facilitate late (beyond 6-mo post-transplant) CNI withdrawal after kidney transplantation in the setting of graft deterioration and BP-CAN. Withdrawal of CNI using MMF or MPS appears to improve serum creatinine and creatinine clearance/GFR in a majority of patients, without an increased risk of proteinuria. The studies also demonstrate a potential for this strategy to improve blood pressure, lipid profile and serum glucose[94]. Benefits of mycophenolic acid derivatives may be offset by in increased risk of acute rejection and infection, so patients should be carefully selected. It appears that concentration-controlling the administration may limit the occurrence of these adverse events and possibly explain differences in adverse effects, such as diarrhea[93,95-97]. Taken individually, these studies were too small and too limited in follow-up to determine an improvement in graft survival, but a meta-analysis did demonstrate a trend toward improvement in graft survival [odds ratio (OR) 0.72, 95%CI: 0.52-1.01, *P* = 0.06] with CNI withdrawal using MMF in a mixed population that was not limited to late withdrawal[98]. Generally speaking, our findings are in line with other recent reviews and meta-analyses, and support a potential role of late CNI elimination with mycophenolic acid derivatives[98-101].

***Regimens utilizing sirolimus to eliminate calcineurin inhibitors***

**Baseline regimen not specified:** The mammalian target of rapamycin inhibitor (mTOR), sirolimus, has also been used to eliminate CNIs. A study[102] evaluated patients more than one year post-transplant with chronic allograft dysfunction according to baseline proteinuria stratification in 3 groups, and either withdrew CNI with addition of sirolimus or reduced the dose of CNI with addition of sirolimus as shown in Table 2[102-118]. As shown, the patients who had sirolimus added demonstrated a statistically significant increase in proteinuria when CNI was withdrawn, but not when CNI was reduced. The post-conversion increase in proteinuria was greater, when the baseline proteinuria value was higher. In addition, when analyzed overall (both withdrawal and continuation combined based on baseline proteinuria) the group with negative baseline proteinuria had a mean 10.4 mL/min (*P* = 0.05) improvement in CrCL over about 2 years, while the group with baseline proteinuria 0.3-0.8 g/d had a mean 7 mL/min (*P* = NS) improvement in CrCL, and the group with baseline proteinuria > 0.8g/d had a 5.5mL/min (*P* = 0.05) decline in CrCL. Taken together these results suggested that use of sirolimus to facilitate CNI withdrawal beyond 1 year had the potential for an adverse impact on renal function that was dependent on the baseline level of proteinuria. Another retrospective study[103] examined 30 patients with unspecified baseline regimen and with about 2 years of follow-up based on indication for switching from CNI to sirolimus, as shown in Table 2. They concluded that sirolimus was associated with an improvement in CrCL and an increase in proteinuria, but that the benefits were achieved only when the conversion occurred within the first year after the transplant[103].

**Baseline corticosteroid and either azathioprine or calcineurin inhibitor:** A cohort study evaluated 19 patients who had sirolimus added and CNI withdrawn by 3 mo for progressive CAN. At 6-mo follow-up, 36% demonstrated improvement in renal function, 21% exhibited stabilization, and 43% resulted in continued worsening. Patients who demonstrated improvement in renal function had lower baseline SCr (2.6 ± 0.9 *vs* 3.3 ± 0.7 mg/dL)[104].

**Baseline calcineurin inhibitor and corticosteroid with or without mycophenolate mofetil:** A retrospective study[105] of patients more than 1 year post-transplant with CAN examined 32 patients for 8.5 mo who had sirolimus added to their regimen and CNI reduced. Only 3 patients had improved SCr (9.4%) and 13 (40.6%) had stable SCr, suggesting that 50% of the population achieved a benefit from the strategy of CNI dose reduction with sirolimus introduction. The authors suggested that the benefit was greater when the baseline SCr was less than 3 mg/dL.

**Baseline tacrolimus and mycophenolate mofetil with or without corticosteroids:** A prospective, randomized study of 200 patients more than 1 year post-transplant, with about 3.5 years follow-up, examined sirolimus addition with trough target 5-8 ng/mL and tacrolimus withdrawal by week 2 (*n* = 123) or continuation of the current regimen with target tacrolimus trough of 6-8 ng/mL. As shown in Table 2, the GFR decreased, and proteinuria increased to a similar degree in both groups during follow-up, with similar acute cellular rejection (ACR) and graft survival, suggesting no tangible benefit to the late switch[106]. In contrast, a cohort study analyzed patients on tacrolimus/MMF or tacrolimus/MMF/corticosteroids with biopsy-proven CAN and progressive renal dysfunction when tacrolimus was converted to sirolimus (10 mg per day for 3 d, then 5 mg/d targeting trough levels 8-10 ng/mL[107]. Overall, SCr decreased and GFR improved, as shown in Table 2. About 1/3 of the patients were non-responders. Although first ACR was about 10%, it was less than the rate observed prior to the conversion (17%). Follow-up biopsies demonstrated significant improvement in interstitial fibrosis and tubular atrophy relative to baseline. It is important to note that this study only included patients who tolerated 90 d of sirolimus therapy[107].

**Baseline CNI with corticosteroids, or CNI with azathioprine, or CNI with mycophenolate mofetil, or CNI with corticosteroids and azathioprine or mycophenolate mofetil:** Two studies evaluated patients with wide variability in baseline regimens[108,109]. One study evaluated patients more than one year post-transplant with biopsy proven CNI toxicity (*n* = 22) and demonstrated a modest decrease in SCr and a 59.1% response rate of improved or lack of progression in renal function deterioration at 6 mo after CNI conversion to sirolimus[108]. The other study evaluated patients more than 6 mo post-transplant with chronic allograft dysfunction or recurrent cancer and demonstrated a modest, non-significant reduction in SCr and increase in CrCL at 27 mo follow-up. However, proteinuria greater than 1 g/d occurred in 20.6% of the population at 2 years[109]. Neither study reported any episodes of ACR[108,109].

**Baseline calcineurin inhibitor, corticosteroid and azathioprine:** A 5-patient cohort with BP-CAN explored conversion from cyclosporine to sirolimus. After 3 mo, SCr nearly doubled and proteinuria increased, at which time patients were converted back to CNI and proteinuria decreased, but SCr continued to rise, and 3 (60%) patients returned to dialysis[110].

**Baseline calcineurin inhibitor, corticosteroid and azathioprine or mycophenolate mofetil:** A retrospective study of patients more than 6 mo post-transplant, with a 20% increase in SCr in 6 mo or a current SCr 2-4.5 mg/dL were converted to sirolimus with CNI withdrawn immediately. At 6 mo, there was a significant reduction in SCr versus baseline, and no evidence of ACR, as shown in Table 2[111]. A prospective, multicentered study of 44 patients more than one year post-transplant with moderate renal insufficiency demonstrated a 7 mL/min (*P* = 0.03) improvement in GFR with a 0.57 g/d increase in proteinuria (*P* = 0.002). Adverse effects observed included an increase in triglycerides, total cholesterol and LDL cholesterol, and a decrease in hemoglobin levels, and one episode of mild ACR[112]. In a cohort of 16 patients with sirolimus added and CNI withdrawn for BP-CAN, 43.8% demonstrated improved, or lack of deterioration in SCr, without an increased risk of ACR. Patients with SCr at baseline < 2.48 mg/dL were more likely to achieve improvement in SCr after the conversion, and patients with higher SCr or C4d deposition in peritubular capillaries were less likely to achieve success[113].

A prospective open-label single-center study conducted by Stallone and colleagues[114] compared a 40% dose reduction in CNI (*n* = 50) with sirolimus addition and CNI elimination (*n* = 34) at greater than 1 year post-transplant[114]. Compared with baseline, CNI reduction resulted in no significant change in SCr, CrCL or proteinuria versus baseline at 2 years follow-up. To a similar degree, SCr, CrCL or proteinuria were similar to baseline in the CNI withdrawal group, although graft survival was improved (84% *vs* 97%, *P* = 0.04). On follow-up biopsies, CAN grade and α-smooth muscle actin (α-SMA) protein expression worsened in the CNI reduction group, and α-SMA decreased (*P* = 0.005) and CAN grade remained stable in the sirolimus group.114 Another study compared sirolimus addition and CNI elimination (*n* = 13) in patients with BP-CAN versus CNI continuation (*n* = 26) in patients with stable renal function, at least 6 mo post-transplant followed patients for 3 years[115]. In that study, sirolimus resulted in an improvement in SCr and GFR, with a statistically significant increase in proteinuria relative to baseline, while CNI continuation resulted in worsening of SCr and GFR and a similar degree of proteinuria. There were more cardiovascular events (*P* = 0.024) in the CNI continuation group, although patient survival was similar. The 3-year change in GFR was the only significant predictor of event-free survival by Cox regression analysis (HR, 0.96, 95%CI: 0.93-0.99, *P* = 0.017), and sirolimus was the strongest predictor of GFR[115].

One retrospective study compared the effects of sirolimus addition and CNI elimination relative to baseline SCr (≥ 140 μmol/L *vs* < 140 μmol/L) and found that patients with more baseline renal dysfunction had a larger decline in SCr relative to baseline, but also developed more proteinuria and had a higher rate of ACR (36.4% *vs* 0%)[116]. Another prospective study targeted sirolimus trough 10-20 ng/mL and CNI elimination over 4 wk, in patients more than 1 year post-transplant, and demonstrated a 5.8 mL/min improvement in CrCL along with a non-significant increase in proteinuria at 12 mo[117].

A randomized, prospective, open-label multicentered comparative trial (CONVERT) evaluated sirolimus to facilitate CNI withdrawal in the setting of concurrent azathioprine or MMF reduction or withdrawal versus continuation of the CNI-based regimen, according to baseline GFR (20-40 mL/min *vs* > 40 mL/min) in patients more than 6 mo post-transplant[118]. As shown in Table 2, patients with GFR > 40 mL/min and converted to sirolimus had a non-significant improvement in GFR relative to baseline and relative to CNI continuation at 24 mo. Patients with baseline GFR 20-40 mL/min had a slightly higher, but still non-significant improvement in GFR at 24 mo relative to CNI continuation. Graft survival was poor in all patients with baseline GFR 20-40 mL/min regardless of regimen (62%-66%). A post-hoc analysis revealed that patients with GFR > 40 mL/min who had a baseline urinary protein-to-creatinine ratio (UPr/Cr) less than or equal to 0.11 had more favorable outcome with sirolimus conversion[118].

**Summary of sirolimus studies:** There appears to be less data comparing sirolimus-facilitated late CNI withdrawal to an active CNI-containing regimen than was found for MPA-facilitated CNI withdrawal. Sirolimus has the potential to support late CNI withdrawal, through a modest improvement in short-term renal function, which has been corroborated in a systematic review[119]. However, the benefit of sirolimus is somewhat limited by an increased risk of proteinuria, especially in the setting of baseline renal dysfunction and/or proteinuria and high rate of discontinuation for adverse effects which ranges from 17% in nonrandomized trials to 28% of randomized trials[119-121]. Adverse effects of sirolimus on renal function were confirmed in a trial which evaluated late sirolimus withdrawal using MMF and found improvement in the slope 1/SCr in 15 of 17 (88%) patients[122]. Renal function results associated with use of sirolimus appear to be improved to a relatively greater degree when sirolimus is used in combination with mycophenolate mofetil[123]. This combination may increase the risk of MMF adverse effects, in part due to a drug-drug interaction[123,124]. It should also be noted that use of reduced dose CNI in conjunction with sirolimus may also suffer from a pharmacokinetic interaction, which potentiates each’s nephrotoxicity[125].

***Regimens utilizing everolimus to eliminate calcineurin inhibitors***

**Baseline calcineurin inhibitor and unspecified adjunctive agents:** A second mTOR inhibitor, everolimus has also generated evidence on late CNI withdrawal in renal transplantation. As shown in Table 3[126-135], a small case series evaluated 21 Hispanic first renal transplant patients (15 cadaveric), including 5 children, who were undergoing conversion from CNI to everolimus with MPA at a mean 8 mo post-transplant, due to CAN or CNI toxicity. Over 10-mo follow-up there was no mortality or graft loss and a slight mean decline of SCr of 0.2 mg/dL, but ACR rate was 17%[126]. Another case series of 78 patients converted CNI to everolimus at a mean 77 mo post-transplant, without manipulation or addition of MPA, and noted a statistically significant mean increase in CrCL of 3.8 mL/min at 3 mo post-conversion, but 12-mo CrCL was not stated. It should be noted that proteinuria increased from baseline at all time points studied, and 16.7% of patients stopped everolimus due to worsening renal function (*n* = 5), dermal eruptions (*n* = 3), or other reasons (*n* = 5)[127]. A case series of 32 patients took patients with deteriorating renal function in the face of CAN and added everolimus to eliminate CNI. At 6-mo, SCr decreased slightly, but not significantly (*P* = 0.07), and proteinuria trended toward an increase (*P* = 0.11)[128]. Of particular interest, a small study retrospectively compared 17 patients with CAN converted to everolimus with 10 patients being converted to everolimus for other reasons. In the CAN group, SCr was higher and CrCL lower at baseline relative to the non-CAN group. SCr in the CAN group decreased steadily out to 2 years follow-up (*P* < 0.05), and CrCL improved significantly, with 100% patient survival. In contrast, the non-CAN group did not demonstrate a significant improvement in SCr or CrCL, and had a 50% mortality rate due to malignancy present at the time of the switch. An increase in proteinuria was observed in both groups[129].

**Baseline calcineurin inhibitor or belatacept with or without mycophenolic acid or azathioprine or corticosteroids:** A retrospective case-control study evaluated patients on a CNI or belatacept with or without MPA or azathioprine or corticosteroids *(n* = 61) converted to everolimus, and another 61 matched patients maintained on CNI-based regimen to determine if DSAs developed after conversion. At mean 36 mo follow-up there was no changes from baseline or between the groups in SCr or CrCL. None of the patients had DSAs at baseline, but the everolimus group had a follow-up incidence of 9.8% (*P* = 0.03) and the CNI continuation group had an incidence of 5% (*P* = NS). The only factor independently associated with DSA development was higher age at transplantation, associated with less DSA formation. Overall, 33% of everolimus patients withdrew from everolimus treatment at a mean 32 mo, due to DSA formation (*n* = 5), lymphedema (*n* = 4), proteinuria (*n* = 3), and other reasons. None of the patients switched back to CNI developed DSAs[130]. Another case series examined 8 patients converted from CNI to everolimus at approximately 5 years post-transplant for CAN or malignancy. Everolimus replaced the CNI in 6 patients and was used to lower the CNI dose 30% in 2 patients. At 1-16 mo, SCr reduced slightly, CrCL improved slightly, and proteinuria:creatinine ratio decreased slightly. Three of the 8 patients developed serious infections[131]. A more robust study, the ASCERTAIN study[132], was a prospective, randomized, open-label, multicenter study with 24 mo follow-up. Patients enrolled were at least 6 mo post-transplant (mean 5.6 years), with renal impairment, and without ACR within 3 mo. The study compared addition of everolimus to eliminate CNI (*n* = 127), addition of everolimus to decreased CNI dose (*n* = 144) and controls maintained on CNI (*n* = 123). Overall, at 24-mo follow-up, ACR rates, graft survival and patient survival were similar. The primary endpoint of the study, CrCL at 24 mo, was not met, because CrCL was similar in all the groups at baseline and at follow-up. Proteinuria increased from baseline and relative to control in the CNI elimination group. Post-hoc analysis showed that patients with a baseline CrCL > 50 mL/min had a larger improvement in CrCL after CNI elimination[132].

**Baseline calcineurin inhibitor with mycophenolic acid or azathioprine and corticosteroids:** In cadaveric recipients on a CNI with MPA or azathioprine and corticosteroids and a SCr > 2 mg/dL with proteinuria less than 1g/24h, everolimus was used to withdraw CNI. CrCL improved from baseline to 3 mo, but no results for 24 mo were presented, although the authors noted a trend toward decline. Proteinuria increased by one month (*P* = 0.05) and more than 3-fold by month 12 (*P* = 0.0106). Two of the 22 patients lost their grafts due to nephrotic syndrome and increasing SCr, and one patient developed ACR[133]. Another study compared 10 patients managed with everolimus to facilitate an 80% CNI dose reduction versus 10 patients with gradual complete CNI elimination. MMF or azathioprine were withdrawn when everolimus was introduced in both groups, but were reintroduced only when the CNI was eliminated. At 12 mo, both groups had similar follow-up SCr, GFR and microalbuminuria, as well as similar changes from baseline. ACR occurred in 10% of the CNI reduction group and none of the CNI elimination group. It is interesting to note that in this study, many of the patients received angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs), which could have impacted the degree of proteinuria. Triglycerides and total cholesterol increased due to everolimus[134].

**Baseline calcineurin inhibitor with everolimus and corticosteroids:** The FOREVER trial[135] examined patients previously enrolled in another trial of CsA with everolimus who either switched CsA to MPS and increased everolimus (*n* = 15) or continued CsA and everolimus. This study, although prospective and randomized, suffered from differences in baseline GFR between the groups that impacted the interpretation of the results. The median (range) baseline measured GFR was 54 (21-87) mL/min in the CsA withdrawal group, and 37 (18-69) mL/min in the CsA continuation group (*P* = 0.053). The difference at follow-up in GFR was -14.4 mL/min for the CsA continuation group, which did not meet statistical significance. Study drugs were discontinued in 7% of the CNI-free patients and 20% of the CNI-treated patients. Adverse event rates were similar, except aphthous stomatitis and pyrexia were more common in the CNI-free group, and hypertension, proteinuria, acute renal failure and urinary tract infection were more common in the CNI-treated patients[135].

**Summary of everolimus studies:** Although the majority of evidence was from small, low-quality studies, there was clear evidence of an increase in proteinuria with conversion to everolimus from a CNI-based regimen, similar to what has been observed with sirolimus[119-121,127-129]. It is interesting to speculate that this may be manageable with ACEI or ARBs[134]. As expected, everolimus also had an adverse effect profile similar to sirolimus[112,122,134,135]. Here was evidence of a modest short-term improvement in renal function after CNI elimination with use of everolimus, and like sirolimus, combination of the mTOR inhibitor and the CNI resulted in enhanced adverse effect profile[122,125,135]. Also, like sirolimus, there was little evidence comparing late CNI withdrawal to an active CNI-containing regimen.

***Regimens utilizing other agents to eliminate calcineurin inhibitors***

**Calcineurin inhibitor and variable adjunctive agents:** A randomized, open label phase II trial[136] evaluated the T cell costimulation blocker, belatacept for comparison with continued CNI in patients 6-36 mo post-transplant. Patients were randomized to switch to belatacept (*n* = 84) intermittent therapy (5 mg/kg on days 1, 15, 29, 43 and 57, followed by every 28 d thereafter), or to continue the current regimen, which consisted of CNI and the current regimen (80.7% corticosteroid, 3.4% azathioprine, and 94.3% MMF or MPA). Patients randomized to belatacept underwent a progressive taper to eliminate CNI by day 29. The primary endpoint was renal function over 12 mo as determined by calculated GFR, and the belatacept group improved 7 ± 11.99 mL/min and the CNI group improved 2.1 ± 10.34 mL/min from baseline (*P* = 0.0058 for comparison at follow-up). Patients in the belatacept group with a baseline CrCL 45-60 mL/min exhibited the greatest numeric improvement (10 ± 13.41 mL/min). Belatacept patients with baseline CrCL < 45 mL/min improved 3.7 ± 11.01 mL/min and patients with CrCL > 60 mL/min improved 5.7 ± 10.17 mL/min. In contrast, patients remaining on CNI exhibited similar CrCL change according to baseline CrCL stratification, ranging from 1.9-2.8 mL/min. Mild to moderate ACR occurred in 6 patients in the belatacept group, all within the first 6 mo. Four of these patients were on belatacept therapy and 2 had discontinued belatacept. SCr returned to baseline in 4 of the 6 patients. No ACR episodes were reported in the CNI continuation group. Proteinuria occurred in one patient in each group. No grafts were lost in either group in the first 12 mo. One patient in the CNI group died with a functioning graft on day 142. Serious adverse event occurred in 24% of the belatacept group and 19% of the CNI continuation group. The biggest discrepancy in the adverse effects, pyrexia occurred in 4% of the belatacept group and 0% of the CNI group[136]. A 2-year follow-up to this study demonstrated 1 additional graft loss in each group, no additional ACR, and a mean change in CrCL from baseline 8.8 mL/min in the belatacept group and 0.3 mL/min in the CNI continuation group. Serious adverse events occurred in 37% of the belatacept group and 33% of the CNI group[137].

**PEDIATRIC PATIENTS 6 OR MORE MONTHS POST-TRANSPLANT**

Pediatric renal transplant patients also commonly receive CNIs and are at risk for potential CNI nephrotoxicity. Based on a comparison with adult kidney transplant recipients, pediatric patients have similar graft survival at 10 years (*P* = 0.4325), with similar rates of delayed graft function and SCr levels. However, acute rejections were more common in pediatric patients, and 10-year patient survival tends to be lower in the pediatric transplant group (90.3% *vs* 76.8%; *P* < 0.02) [138]. Consequently, pediatric patients are at similar or greater risks as adult patients, depending on the endpoint studied, and thus may be considered for immunosuppression changes from CNIs over time[139].

***Regimens using mycophenolic acid or sirolimus to eliminate CNIs***

**CNI and variable regimen:** Weintraub and colleagues retrospectively evaluated 17 patients on a baseline regimen of CNI plus either sirolimus, MMF or azathioprine, with or without corticosteroids who were being switched to sirolimus or MMF for CNI toxicity (*n* = 9), CAN (*n* = 6) or diabetes mellitus (*n* = 2) at a mean 5.9 years post-transplant. Mean CrCL actually decreased from baseline after the switch at 6 mo (*P* = 0.04) and 12 mo (*P* = 0.02), and 41% of patient developed ACR. Risk of ACR was predicted by prior AR history, which was present in 9 of 17 patients, lower sirolimus trough levels, and lower calcineurin inhibitor toxicity scores. Graft loss occurred in 24% of patients and was associated with worse CrCL, proteinuria, and histologic chronicity. Proteinuria increased in a manner unrelated to sirolimus use. Four patients returned to a CNI-base regimen based on adverse effects. The authors suggested that worsened graft function and graft loss after conversion could be minimized by selecting patients with high CNI toxicity scores and low chronicity scores on biopsy, and excluding patients with a history of ACR[140].

***Regimens using mycophenolic acid to eliminate CNIs***

**Baseline CNI, corticosteroid and azathioprine :** In another study of patients averaging 40 mo post-transplant, but at least 3 mo post-transplant, conversion from CNI, azathioprine and corticosteroid to MMF plus corticosteroid (*n* = 29) or addition of MMF and elimination of azathioprine, without CNI withdrawal (*n* = 9) resulted in overall patient survival of 100% and graft survival of 94% at approximately 5-year follow-up. There was no significant difference in ACR or proteinuria between the groups. Introduction of MMF resulted in improvement in GFR over 2 year regardless of which group was evaluated, but the patients with CNI withdrawn had a numerically increased GFR[141].

***Regimens using sirolimus and MMF to eliminate CNI***

**Baseline calcineurin inhibitor, corticosteroid and azathioprine:** A group retrospectively analyzed addition of sirolimus and MMF to eliminate CNI, and compared the strategy to CNI minimization (39% dose reduction), MMF and corticosteroid. One year after conversion, the sirolimus group had a 10.3 ± 3 mL/min improvement in CrCL (*P* < 0.05) versus baseline, while the CNI minimization group had a 17.7 ± 7.1 mL/min (*P* < 0.05) improvement in CrCL. No patient experienced ACR in either group. The authors concluded that sirolimus and MMF introduction had similar benefit to MMF introduction with CNI minimization[142].

**Summary of pediatric studies:** Data is currently very limited on late CNI withdrawal to improve renal function and further study is required. Patient characteristics may impact the success of selected regimens.

**CONCLUSION**

This manuscript presents available evidence on late conversion, beyond 6 mo, from CNIs to alternative regimens as a means to aid practicing clinicians in determining therapeutic options for patients exhibiting CNI toxicity or CAN. Although recent evidence suggests that CNI toxicity and CAN are non-specific findings, and graft dysfunction may alternatively or additionally be a function of C4d and DSA, it has been shown that 5-year graft survival is not independently predicted by DSA and C4d, suggesting that clinicians will still modify regimens based on the presence of CAN and CNI toxicity on biopsy[143-145]. These studies provide moderate-level evidence of a short-term improvement in renal function, that is not without regimen-specific risks, such as increased infection rate with MPA or proteinuria with mTOR inhibitors. There appears to be a “point of no return” after which kidney damage is irreversible and the patient stands to benefit less from withdrawal of CNI[103-105,132]. Since the benefit of late withdrawal appears to be modest and dependent on baseline renal function, the second manuscript in this series will evaluate the data surrounding early conversion and de novo CNI avoidance.

**REFERENCES**

1 **Wolfe RA**, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med* 1999; **341**: 1725-1730 [PMID: 10580071 DOI: 10.1056/NEJM199912023412303]

2 **Tonelli M**, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. *Am J Transplant* 2011; **11**: 2093-2109 [PMID: 21883901 DOI: 10.1111/j.1600-6143.2011.03686]

3 **Fiebiger W**, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. *Health Qual Life Outcomes* 2004; **2**: 2 [PMID: 14713316 DOI: 10.1186/1477-7525-2-2]

4 **Ojo AO**, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, Agodoa LY, Kaplan B, Port FK. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. *J Am Soc Nephrol* 2001; **12**: 589-597 [PMID: 11181808]

5 **Meier-Kriesche HU**, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. *Am J Transplant* 2004; **4**: 378-383 [PMID: 14961990 DOI: 10.1111/j.1600-6143.2004.00332.x]

6 **Tantravahi J**, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? *Annu Rev Med* 2007; **58**: 369-385 [PMID: 17002551 DOI: 10.1146/annurev.med.58.061705.145143]

7 **Naesens M**, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol* 2009; **4**: 481-508 [PMID: 19218475 DOI: 10.2215/CJN.04800908]

8 **Tanabe K**. Calcineurin inhibitors in renal transplantation: what is the best option? *Drugs* 2003; **63**: 1535-1548 [PMID: 12887261]

9 **Hernández D**, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. *Transplantation* 2007; **84**: 706-714 [PMID: 17893603]

10 **Artz MA**, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Blom HJ, Sweep FC, Demacker PN, Hilbrands LB. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. *J Am Soc Nephrol* 2003; **14**: 1880-1888 [PMID: 12819249 DOI: 10.1097/01.ASN.0000071515.27754.67]

11 **Artz MA**, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P, Borm G, Hilbrands LB. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. *Am J Transplant* 2004; **4**: 937-945 [PMID: 15147428 DOI: 10.1111/j.1600-6143.2004.00427.x]

12 **Shihab FS**, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, Henning AK, Holman J, First MR. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. *Transplantation* 2008; **85**: 1261-1269 [PMID: 18475181 DOI: 10.1097/TP.0b013e31816b4388]

13 **Meier M**, Nitschke M, Weidtmann B, Jabs WJ, Wong W, Suefke S, Steinhoff J, Fricke L. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. *Transplantation* 2006; **81**: 1035-1040 [PMID: 16612281]

14 **Vincenti F**, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant* 2007; **7**: 1506-1514 [PMID: 17359512 DOI: 10.1111/j.1600-6143.2007.01749.x]

15 **Nashan B**, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. *Transplantation* 2002; **73**: S3-11 [PMID: 12023607]

16 **Jacobson PA**, Schladt D, Israni A, Oetting WS, Lin YC, Leduc R, Guan W, Lamba V, Matas AJ. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. *Transplantation* 2012; **93**: 624-631 [PMID: 22334041 DOI: 10.1097/TP.0b013e3182461288]

17 **Kuypers DR**, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. *Ther Drug Monit* 2010; **32**: 394-404 [PMID: 20526235 DOI: 10.1097/FTD.0b013e3181e06818]

18 **Kuypers DR**, de Jonge H, Naesens M, Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. *Clin Ther* 2010; **32**: 2012-2023 [PMID: 21118736 DOI: 10.1016/j.clinthera.2010.11.010]

19 **de Jonge H**, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. *Clin Pharmacol Ther* 2011; **90**: 414-422 [PMID: 21753749 DOI: 10.1038/clpt.2011.130]

20 **Mino Y**, Naito T, Otsuka A, Takayama T, Ozono S, Kagawa Y, Kawakami J. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase. *J Clin Pharm Ther* 2011; **36**: 217-224 [PMID: 21366651 DOI: 10.1111/j.1365-2710.2010.01168.x]

21 **Cosio FG**, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. *Am J Transplant* 2005; **5**: 2464-2472 [PMID: 16162196 DOI: 10.1111/j.1600-6143.2500.01050.x]

22 **Snanoudj R**, Royal V, Elie C, Rabant M, Girardin C, Morelon E, Kreis H, Fournet JC, Noël LH, Legendre C. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. *Am J Transplant* 2011; **11**: 2635-2646 [PMID: 21883915 DOI: 10.1111/j.1600-6143.2011.03718.x]

23 **Matas AJ**, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, Halloran P, Hunsicker L, Cosio F, Grande J, Mannon R, Gourishankar S, Gaston R, Kasiske B. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. *Am J Transplant* 2010; **10**: 315-323 [PMID: 20041864 DOI: 10.1111/j.1600-6143.2009.02943.x]

24 **Terasaki PI**, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. *Transplantation* 2005; **80**: 1194-1197 [PMID: 16314785 DOI: 10.1097/01.tp.0000174338.97313.5a]

25 **Sellarés J**, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant* 2012; **12**: 388-399 [PMID: 22081892 DOI: 10.1111/j.1600-6143.2011.03840.x]

26 **Nankivell BJ**, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; **349**: 2326-2333 [PMID: 14668458 DOI: 10.1056/NEJMoa020009]

27 **Paul LC**. Chronic allograft nephropathy: An update. *Kidney Int* 1999; **56**: 783-793 [PMID: 10469349 DOI: 10.1046/j.1523-1755.1999.00611.x]

28 **Chapman JR**, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. *J Am Soc Nephrol* 2005; **16**: 3015-3026 [PMID: 16120819 DOI: 10.1681/ASN.2005050463]

29 **Grinyo JM**, Saval N, Campistol JM. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients. *Nephrol Dial Transplant* 2011; **26**: 3750-3755 [PMID: 21474575 DOI: 10.1093/ndt/gfr091]

30 **Chapman JR**. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. *Am J Transplant* 2011; **11**: 693-697 [PMID: 21446974 DOI: 10.1111/J.1600-6143.2011.03504.x]

31 **Weir MR**, Wali RK. Minimizing the risk of chronic allograft nephropathy. *Transplantation* 2009; **87**: S14-S18 [PMID: 19384181 DOI: 10.1097/TP.0b013e3181a079c0]

32 **Meier-Kriesche HU**, Chu AH, David KM, Chi-Burris K, Steffen BJ. Switching immunosuppression medications after renal transplantation--a common practice. *Nephrol Dial Transplant* 2006; **21**: 2256-2262 [PMID: 16574677 DOI: 10.1093/ndt/gfl134]

33 **Opelz G**, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. *Transplantation* 2008; **86**: 371-376 [PMID: 18698238 DOI: 10.1097]

34 **Knoll GA**, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. *J Am Soc Nephrol* 2003; **14**: 2381-2386 [PMID: 12937317 DOI: 10.1097/01.ASN.0000079616.71891.F5]

35 **Pascual J**, Marcén R, Ortuño J. Renal function: defining long-term success. *Nephrol Dial Transplant* 2004; **19 Suppl 6**: vi3-vi7 [PMID: 15575023 DOI: 10.1093/ndt/gfh1062]

36 **Kaplan B**, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. *J Am Soc Nephrol* 2003; **14**: 2980-2984 [PMID: 14569110 DOI: 10.1097/01.ASN.0000095250.92361.D5]

37 **Cheung CY**, Wong KM, Chan HW, Liu YL, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Li CS. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients. *Transpl Int* 2006; **19**: 657-666 [PMID: 16827683 DOI: 10.1111/j.1432-2277.2006.00335.x]

38 **Stegall MD**, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, Dean PG, Prieto M, Amer H, Textor S, Schwab T, Cosio FG. The histology of solitary renal allografts at 1 and 5 years after transplantation. *Am J Transplant* 2011; **11**: 698-707 [PMID: 21062418 DOI: 10.1111/j.1600-6143.2010.03312.x]

39 **Sprangers B**, Kuypers DR, Vanrenterghem Y. Immunosuppression: does one regimen fit all? *Transplantation* 2011; **92**: 251-261 [PMID: 21593703]

40 **Srinivas TR**, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. *Clin J Am Soc Nephrol* 2008; **3 Suppl 2**: S101-S116 [PMID: 18308998 DOI: 10.2215/CJN.03510807]

41 **Bestard O**, Cruzado JM, Grinyó JM. Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability? *Drugs* 2006; **66**: 403-414 [PMID: 16597159 DOI: 10.2165/00003495-200666040-00001]

42 **Pascual J**, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrol Dial Transplant* 2012; **27**: 825-832 [PMID: 21785040 DOI: 10.1093/ndt/gfr374]

43 **Yang H**. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance. *Am J Kidney Dis* 2006; **47**: S37-S51 [PMID: 16567240 DOI: 10.1053/j.ajkd.2005.12.045]

44 **Kirk AD**, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. *Transplant Int* 2005; **18**: 2-14 [PMID 15612977 DOI: 10.1111/j.1432-2277.2004.00019.x]

45 **Giessing M**, Fuller TF, Tuellmann M, Slowinski T, Budde K, Liefeldt L. Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. *World J Urol* 2007; **25**: 325-332 [PMID: 17333201 DOI: 10.1007/s00345-007-0157-8]

46 **Augustine JJ**, Hricik DE. Minimization of immunosuppression in kidney transplantation. *Curr Opin Nephrol Hypertens* 2007; **16**: 535-541 [PMID: 18089967]

47 **Helal I**, Chan L. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. *Transplant Proc* 2011; **43**: 472-477 [PMID: 21440737 DOI: 10.1016/j.transproceed.2011.01.054]

48 **Olyaei AJ**, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. *Curr Opin Crit Care* 2001; **7**: 384-389 [PMID: 11805539]

49 **Flechner SM**. Minimizing calcineurin inhibitor drugs in renal transplantation. *Transplant Proc* 2003; **35**: 118S-121S [PMID: 12742481 DOI: 10.1016/S0041-1345(03)00218-5]

50 **Lo A**. Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors. *Prog Transplant* 2004; **14**: 157-164 [PMID: 15264460]

51 **Bestard O**, Cruzado JM, Grinyó JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. *Transplant Proc* 2005; **37**: 3729-3732 [PMID: 16386520 DOI: 10.1016/j.transproceed.2005.09.129]

52 **Guerra G**, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. *Transpl Int* 2007; **20**: 813-827 [PMID: 17645419 DOI: 10.1111/j.1432-2277.2007.00528.x]

53 **Barbari AG**, Stephan AG, Masri MA. Calcineurin inhibitor-free protocols: risks and benefits. *Saudi J Kidney Dis Transpl* 2007; **18**: 1-23 [PMID: 17237886]

54 **Flechner SM**, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. *Clin Transplant* 2008; **22**: 1-15 [PMID: 18217899 DOI: 10.1111/j.1399-0012.2007.00739.x]

55 **Golshayan D**, Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. *Transpl Immunol* 2008; **20**: 21-28 [PMID: 18775494 DOI: 10.1016/j.trim.2008.08.006]

56 **Ekberg H**. Calcineurin inhibitor sparing in renal transplantation. *Transplantation* 2008; **86**: 761-767 [PMID: 18813097 DOI: 10.1097/TP.0b013e3181856f39]

57 **Grinyó JM**, Bestard O, Torras J, Cruzado JM. Optimal immunosuppression to prevent chronic allograft dysfunction. *Kidney Int Suppl* 2010; **78**: S66-S70 [PMID: 21116321 DOI: 10.1038/ki.2010.426]

58 **Sharif A**, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. *J Am Soc Nephrol* 2011; **22**: 2107-2118 [PMID: 21949096 DOI: 10.1681/ASN.2010111160]

59 **Vincenti F**. Are calcineurin inhibitors-free regimens ready for prime time? *Kidney Int* 2012; **82**: 1054-1060 [PMID: 22622502 DOI: 10.1038/ki.2012.194]

60 **Ruiz R**, Klintmalm GB. Renal-sparing regimens employing new agents. *Curr Opin Organ Transplant* 2012; **17**: 619-625 [PMID: 23111644 DOI: 10.1097/MOT.0b013e328359886a]

61 **Mathis AS**. Kidney transplantation: a pharmacist-focused discussion of common clinical issues related to comorbidities, renal function, and organ rejection. *Pharmacy Times* 2013; **79**: 87-99

62 **Salvadori M**, Bertoni E. Is it time to give up with calcineurin inhibitors in kidney transplantation? *World J Transplant* 2013; **3**: 7-25 [PMID: 24175203 DOI: 10.5500/wjt.v3.i2.7]

63 **Tönshoff B**, Höcker B. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. *Pediatr Transplant* 2006; **10**: 721-729 [PMID: 16911497 DOI: 10.1111/j.1399-3046.2006.00577.x]

64 **Sarwal M**, Pascual J. Immunosuppression minimization in pediatric transplantation. *Am J Transplant* 2007; **7**: 2227-2235 [PMID: 17711553 DOI: 10.1111/j.1600-6143.2007.01936.x]

65 **Tredger JM**, Brown NW, Dhawan A. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum. *Drugs* 2008; **68**: 1385-1414 [PMID: 18578558]

66 **Höcker B**, Tönshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? *Paediatr Drugs* 2011; **13**: 49-69 [PMID: 21162600 DOI: 10.2165/11538530-000000000-00000]

67 **He J**, Li Y, Zhang H, Wei X, Zheng H, Xu C, Bao X, Yuan X, Hou J. Immune function assay (ImmuKnow) as a predictor of allograft rejection and infection in kidney transplantation. *Clin Transplant* 2013; **27**: E351-E358 [PMID: 23682828 DOI: 10.1111/ctr.12134]

68 **Ashton-Chess J**, Giral M, Soulillou JP, Brouard S. Can immune monitoring help to minimize immunosuppression in kidney transplantation? *Transpl Int* 2009; **22**: 110-119 [PMID: 18764832 DOI: 10.1111/j.1432-2277.2008.00748.x]

69 **Danger R**, Giral M, Soulillou JP, Brouard S. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. *Curr Opin Organ Transplant* 2008; **13**: 609-613 [PMID: 19060551 DOI: 10.1097/MOT.0b013e3283193bd8]

70 **Henderson LK**, Nankivell BJ, Chapman JR. Surveillance protocol kidney transplant biopsies: their evolving role in clinical practice. *Am J Transplant* 2011; **11**: 1570-1575 [PMID: 21797971 DOI: 10.1111/j.1600-6143.2011.03677.x]

71 **Roos-van Groningen MC**, Scholten EM, Lelieveld PM, Rowshani AT, Baelde HJ, Bajema IM, Florquin S, Bemelman FJ, de Heer E, de Fijter JW, Bruijn JA, Eikmans M. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. *J Am Soc Nephrol* 2006; **17**: 881-888 [PMID: 16467444 DOI: 10.1681/ASN.2005080891]

72 **Rowshani AT**, Scholten EM, Bemelman F, Eikmans M, Idu M, Roos-van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, ten Berge I, Florquin S. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. *J Am Soc Nephrol* 2006; **17**: 305-312 [PMID: 16306168 DOI: 10.1681/ASN.2005030249]

73 **Sis B**, Dadras F, Khoshjou F, Cockfield S, Mihatsch MJ, Solez K. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. *Am J Transplant* 2006; **6**: 1444-1450 [PMID: 16686769 DOI: 10.1111/j.1600-6143.2006.01302.x]

74 **Gotti E**, Perico N, Perna A, Gaspari F, Cattaneo D, Caruso R, Ferrari S, Stucchi N, Marchetti G, Abbate M, Remuzzi G. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. *J Am Soc Nephrol* 2003; **14**: 755-766 [PMID: 12595513 DOI: 10.1097/01.ASN.0000048717.97169.29]

75 **Hauser IA**, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. *J Am Soc Nephrol* 2005; **16**: 1501-1511 [PMID: 15772250 DOI: 10.1681/ASN.2004100882]

76 **van de Wetering J**, Koumoutsakos P, Peeters A, van der Mast BJ, de Kuiper P, IJzermans JN, Weimar W, Baan CC. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation. *Clin Transplant* 2011; **25**: 40-46 [PMID: 20636406 DOI: 10.1111/j.1399-0012.2010.01311.x]

77 **Toz H**, Sen S, Celik HA, Yilmaz M, Hur E, Hoscoskun C, Ozkahya M, Aydin HH. Calcineurin inhibitor-based and free regimens have distinct gene expression patterns in subclinical graft fibrosis. *Ann Transplant* 2011; **16**: 76-87 [PMID: 21716190]

78 **Jevnikar AM**, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. *Clin J Am Soc Nephrol* 2008; **3 Suppl 2**: S56-S67 [PMID: 18309004 DOI: 10.2215/CJN.03040707]

79 **Kasiske BL**, Heim-Duthoy K, Ma JZ. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. *JAMA* 1993; **269**: 395-400 [PMID: 8418349 DOI: 10.1001/jama.1993.03500030093040]

80 **van der Mast BJ**, van Besouw NM, Witvliet MD, de Kuiper P, Smak Gregoor P, van Gelder T, Weimar W, Claas FH. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression. *Transplantation* 2003; **75**: 871-877 [PMID: 12660517]

81 **Ojo AO**, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; **69**: 2405-2409 [PMID: 10868649]

82 **Busque S**, Shoker A, Landsberg D, McAlister V, Halloran P, Shapiro J, Peets J, Schulz M. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. *Transplant Proc* 2001; **33**: 1266-1267 [PMID: 11267285]

83 **Kosch M**, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. *Transplantation* 2003; **76**: 1516-1519 [PMID: 14657697]

84 **Suwelack B**, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. *Am J Transplant* 2004; **4**: 655-662 [PMID: 15023160 DOI: 10.1111/j.1600-6143.2004.00404.x]

85 **McGrath JS**, Shehata M. Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. *Transplant Proc* 2001; **33**: 2193-2195 [PMID: 11377500]

86 **Hanvesakul R**, Kubal C, Jham S, Sarkar E, Eardley K, Adu D, Cockwell P. Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. *Nephrol Dial Transplant* 2008; **23**: 4049-4053 [PMID: 18622022 DOI: 10.1093/ndt/gfn387]

87 **Dudley C**, Pohanka E, Riad H, Dedochova J, Wijngaard P, Sutter C, Silva HT. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. *Transplantation* 2005; **79**: 466-475 [PMID: 15729174 DOI: 10.1097/01.TP.0000151632.21551.00]

88 **Weir MR**, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. *Kidney Int* 2001; **59**: 1567-1573 [PMID: 11260422 DOI: 10.1046/j.1523-1755.2001.0590041567.x]

89 **Weir MR**, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. *Am J Nephrol* 2004; **24**: 379-386 [PMID: 15237243 DOI: 10.1159/000079390]

90 **Abramowicz D**, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P, Fung S. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. *Transplantation* 2002; **74**: 1725-1734 [PMID: 12499889 DOI: 10.1097/01.TP.0000038729.43731.F6]

91 **Abramowicz D**, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. *J Am Soc Nephrol* 2005; **16**: 2234-2240 [PMID: 15917338 DOI: 10.1681/ASN.2004100844]

92 **Heeg MH**, Mueller GA, Bramlage C, Homayounfar K, Muehlhausen J, Leha A, Koziolek MJ. Improvement of renal graft function after conversion from a calcineurin inhibitor including immunosuppression to a mycophenolate sodium including regimen: a 4-year follow-up. *Transplant Proc* 2013; **45**: 142-147 [PMID: 23375288 DOI: 10.1016/j.transproceed.2012.10.028]

93 **Mourer JS**, Hartigh Jd, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. *Transplantation* 2012; **93**: 887-894 [PMID: 22538450 DOI: 10.1097/TP.0b013e31824ad60a]

94 **Mathis AS**, Davé N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. *Am J Health Syst Pharm* 2004; **61**: 565-85; quiz 586-7 [PMID: 15061429]

95 **Kuypers DR**, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. *Ther Drug Monit* 2003; **25**: 609-622 [PMID: 14508385]

96 **Kuypers DR**, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. *Clin Ther* 2008; **30**: 673-683 [PMID: 18498916]

97 **Hohage H**, Zeh M, Heck M, Gerhardt UW, Welling U, Suwelack BM. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. *Transplant Proc* 2005; **37**: 1748-1750 [PMID: 15919453]

98 **Moore J**, Middleton L, Cockwell P, Adu D, Ball S, Little MA, Ready A, Wheatley K, Borrows R. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. *Transplantation* 2009; **87**: 591-605 [PMID: 19307799 DOI: 10.1097/TP.0b013e318195a421]

99 **Land W**, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. *Transplantation* 2005; **80**: S221-S234 [PMID: 16251855]

100 **Dalal P**, Grafals M, Chhabra D, Gallon L. Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. *Ther Clin Risk Manag* 2009; **5**: 139-149 [PMID: 19436616]

101 **Grinyó JM**, Cruzado JM. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. *Am J Transplant* 2009; **9**: 2447-2452 [PMID: 19775321 DOI: 10.1111/j.1600-6143.2009.02812.x]

102 **Gutiérrez MJ**, González E, Andrés A, Morales JM. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. *Transplant Proc* 2009; **41**: 2348-2350 [PMID: 19715916 DOI: 10.1016/j.transproceed.2009.06.163]

103 **Maharaj S**, Assounga AG. Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population. *Exp Clin Transplant* 2010; **8**: 14-18 [PMID: 20199366]

104 **Citterlo F**, Scatà MC, Violi P, Romagnoli J, Pozzetto U, Nanni G, Castagneto M. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. *Transplant Proc* 2003; **35**: 1292-1294 [PMID: 12826140 DOI: 10.1016/S0041-1345(03)00375-0]

105 **Wu MJ**, Shu KH, Cheng CH, Chen CH. Sirolimus in chronic allograft nephropathy. *Transplant Proc* 2004; **36**: 2053-2055 [PMID: 15518743 DOI: 10.1016/j.transproceed.2004.08.005]

106 **Chhabra D**, Alvarado A, Dalal P, Leventhal J, Wang C, Sustento-Reodica N, Najafian N, Skaro A, Levitsky J, Mas V, Gallon L. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. *Am J Transplant* 2013; **13**: 2902-2911 [PMID: 24007570 DOI: 10.1111/ajt.12437]

107 **Wali RK**, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinits M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. *Am J Transplant* 2007; **7**: 1572-1583 [PMID: 17511682 DOI: 10.1111/j.1600-6143.2007.01825.x]

108 **Diekmann F**, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. *Transplant Proc* 2001; **33**: 3234-3235 [PMID: 11750386 DOI: 10.1016/S0041-1345(01)02375-2]

109 **Bumbea V**, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. *Nephrol Dial Transplant* 2005; **20**: 2517-2523 [PMID: 15985508 DOI: 10.1093/ndt/gfh957]

110 **Boratyńska M**, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. *Transplant Proc* 2006; **38**: 101-104 [PMID: 16504675 DOI: 10.1016/j.transproceed.2005.12.023]

111 **Martínez-Mier G**, Méndez-López MT, Estrada-Oros J, Budar-Fernandez LF, Soto-González JI, Méndez-Machado GF, Viñas Dozal JC. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients. *Arch Med Res* 2006; **37**: 635-638 [PMID: 16740435 DOI: 10.1016/j.arcmed.2005.12.003]

112 **Kamar N**, Frimat L, Blancho G, Wolff P, Delahousse M, Rostaing L. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. *Transpl Int* 2007; **20**: 128-134 [PMID: 17239020 DOI: 10.1111/j.1432-2277.2006.00409.x]

113 **Chen J**, Li L, Wen J, Tang Z, Ji S, Sha G, Cheng Z, Sun Q, Cheng D, Liu Z. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy. *Transplant Proc* 2008; **40**: 1411-1415 [PMID: 18589119 DOI: 10.1016/j.transproceed.2008.03.096]

114 **Stallone G**, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, Gesualdo L, Schena FP, Grandaliano G. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. *J Am Soc Nephrol* 2005; **16**: 3755-3762 [PMID: 16236802 DOI: 10.16\_1/ASN.2005060635]

115 **Paoletti E**, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction. *J Nephrol* 2012; **25**: 709-718 [PMID: 22038336 DOI: 10.5301/jn.5000044]

116 **Alarrayed SM**, El-Agroudy AE, Alarrayed AS, Al Ghareeb SM, Garadah TS, El-Sharqawi SY, Al-Aradi AH, Dandi BG, Abdulla S. Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience. *Clin Exp Nephrol* 2010; **14**: 248-255 [PMID: 20232105 DOI: 10.1007/s10157-010-0269-0]

117 **Fischereder M**, Graeb C, Krüger B, Kammerl MC, Zülke C, Jauch KW, Krämer BK. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. *Transplant Proc* 2006; **38**: 1295-1297 [PMID: 16797286 DOI: 10.1016/j.transproceed.2006.03.026]

118 **Schena FP**, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. *Transplantation* 2009; **87**: 233-242 [PMID: 19155978 DOI: 10.1097/TP.0b013e3181927a41]

119 **Mulay AV**, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. *Transplantation* 2006; **82**: 1153-1162 [PMID: 17102766 DOI: 10.1097/01.tp.0000237101.58974.43]

120 **van den Akker JM**, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. *Kidney Int* 2006; **70**: 1355-1357 [PMID: 16912706 DOI: 10.1038/sj.ki.5001792]

121 **Rangan GK**. Sirolimus-associated proteinuria and renal dysfunction. *Drug Saf* 2006; **29**: 1153-1161 [PMID: 17147461]

122 **Kaplan B**, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU. Effect of sirolimus withdrawal in patients with deteriorating renal function. *Am J Transplant* 2004; **4**: 1709-1712 [PMID: 15367229 DOI: 10.111/j.1600-6143.2004.00569.x]

123 **Grinyó JM**, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. *Am J Transplant* 2006; **6**: 1991-1999 [PMID: 16930395 DOI: 10.1111/j.1600-1643.2006.01398.x]

124 **Pescovitz MD**, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. *Br J Clin Pharmacol* 2007; **64**: 758-771 [PMID: 17555465 DOI: 10.1111/j.1365-2125.2007.02934.x]

125 **Meier-Kriesche HU**, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. *Am J Transplant* 2005; **5**: 2273-2280 [PMID: 16095509 DOI: 10.1111/j.1600-1643.2005.01019.x]

126 **Giron F**, Baez Y, Niño-Murcia A, Rodríguez J, Salcedo S. Conversion therapy to everolimus in renal transplant recipients: results after one year. *Transplant Proc* 2008; **40**: 711-713 [PMID: 18454994 DOI: 10.1016/j.transproceed.2008.03.012]

127 **Sánchez Fructuoso A**, Ruiz San Millán JC, Calvo N, Rodrigo E, Moreno MA, Cotorruelo J, Conesa J, Gómez-Alamillo C, Arias M, Barrientos A. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. *Transplant Proc* 2007; **39**: 2148-2150 [PMID: 17889120 DOI: 10.1016/j.transproceed.2007.06.030]

128 **Ruiz JC**, Sanchez-Fructuoso A, Rodrigo E, Conesa J, Cotorruelo JG, Gómez-Alamillo C, Calvo N, Barrientos A, Arias M. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. *Transplant Proc* 2006; **38**: 2424-2426 [PMID: 17097956 DOI: 10.1016/j.transproceed.2006.08.190]

129 **Fernández A**, Marcén R, Galeano C, Caldés S, Amezquita Y, Villafruela J, Pascual J, Burgos J, Rodríguez-Mendiola N, Ortuño J. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. *Transplant Proc* 2009; **41**: 2345-2347 [PMID: 19715915 DOI: 10.1016/j.transproceed.2009.06.162]

130 **Kamar N**, Del Bello A, Congy-Jolivet N, Guilbeau-Frugier C, Cardeau-Desangles I, Fort M, Esposito L, Guitard J, Gamé X, Rostaing L. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. *Clin Transplant* 2013; **27**: 455-462 [PMID: 23621682 DOI: 10.1111/ctr.12127]

131 **Morales J**, Fierro A, Benavente D, Zehnder C, Ferrario M, Contreras L, Herzog C, Buckel E. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. *Transplant Proc* 2007; **39**: 591-593 [PMID: 17445551 DOI: 10.1016/j.transproceed.2007.12.026]

132 **Holdaas H**, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. *Transplantation* 2011; **92**: 410-418 [PMID: 21697773 DOI: 10.1097/TP.0b013e318224c12d]

133 **Inza A**, Balda S, Alvarez E, Zárraga S, Gaínza FJ, Lampreabe I. Conversion to everolimus in kidney transplant recipients with decreased renal function. *Transplant Proc* 2009; **41**: 2134-2136 [PMID: 19715854 DOI: 10.1016/j.transproceed.2009.05.013]

134 **Cataneo-Dávila A**, Zúñiga-Varga J, Correa-Rotter R, Alberú J. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. *Transplant Proc* 2009; **41**: 4138-4146 [PMID: 20005355 DOI: 10.1016/j.transproceed.2009.08.065]

135 **Albano L**, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, Tetaz R, Moal MC, Kamar N, Legendre C, Quéré S, Di Giambattista F, Terpereau A, Dantal J. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. *Ann Transplant* 2012; **17**: 58-67 [PMID: 22466910 DOI: 10.12659/AOT.882637]

136 **Rostaing L**, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. *Clin J Am Soc Nephrol* 2011; **6**: 430-439 [PMID: 21051752 DOI: 10.2215/CJN.05840710]

137 **Grinyo J**, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. *Transpl Int* 2012; **25**: 1059-1064 [PMID: 22816557 DOI: 10.1111/j.1432-2277.2012.01535.x]

138 **Parada B**, Figueiredo A, Nunes P, Bastos C, Macário F, Roseiro A, Dias V, Rolo F, Mota A. Pediatric renal transplantation: comparative study with renal transplantation in the adult population. *Transplant Proc* 2005; **37**: 2771-2774 [PMID: 16182806 DOI: 10.1016/j.transproceed.2005.05.046]

139 **Kari JA**, Trompeter RS. What is the calcineurin inhibitor of choice for pediatric renal transplantation? *Pediatr Transplant* 2004; **8**: 437-444 [PMID: 15367278]

140 **Weintraub L**, Li L, Kambham N, Alexander S, Concepcion W, Miller K, Wong C, Salvatierra O, Sarwal M. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. *Pediatr Transplant* 2008; **12**: 541-549 [PMID: 18564305 DOI: 10.1111/j.1399-3046.2007.00847.x]

141 **Krischock L**, Gullett A, Bockenhauer D, Rees L, Trompeter RS, Marks SD. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection. *Pediatr Transplant* 2009; **13**: 475-481 [PMID: 18992054]

142 **Höcker B**, Feneberg R, Köpf S, Weber LT, Waldherr R, Wühl E, Tönshoff B. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. *Pediatr Transplant* 2006; **10**: 593-601 [PMID: 16856996 DOI: 10.1111/j.1399-3046.2006.00526.x]

143 **Gourishankar S**, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, Gaston R, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J, Mannon R, Matas A. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. *Am J Transplant* 2010; **10**: 324-330 [PMID: 20055809 DOI: 10.1111/j.1600-6143.2009.02954.x]

144 **Gaston RS**, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. *Transplantation* 2010; **90**: 68-74 [PMID: 20463643 DOI: 10.1097/TP.0b013e3181e065de]

145 **Rush D**, Leduc R, Connett J, Cosio F, Gaston R, Mannon R, Hunsicker L, Gourishankar S, Halloran P, Cecka M, Grande J, Kasiske B. DeKAF pathology clusters: follow up at 5 years. *Am j Transplant* 2013; **19**: 417 [DOI: 10.1111/ajt.12266]

**P-Reviewers:** Akoh JA, Kavukcu S, Lee PC **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 renal transplant studies utilizing mycophenolic acid to withdraw calcineurin inhibitor beyond 6 mo post-transplant (“Late”)[83-93]**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Design | Population (N) | Baseline Regimen | N | Strategy | Follow-up | Renal function | Acute rejection | Graft survival | Patient survival |
| Kosch *et al*[83] | Prospective, randomized, single-center | 6-mo of deteriorating renal function, BP-CAN | CsA, Prednisolone | 12 | MMF added, target 2 g per day; CsA withdrawn over 4 wk | 6 mo | SCr +0.03 mg/dL *vs* baseline (*P* = NS) | NA | NA | NA |
|  |  |  |  | 12 | MMF added, target 2 g; CsA continued |  | SCr + 0.07 mg/dL *vs* baseline (*P* = NS) | NA | NA | NA |
| Suwelack *et al*[84] | Prospective, randomized, single-center | > 1-yr post transplant, SCr < 4 mg/dL, BP-CAN, deteriorating renal function | CsA or TAC, Prednisolone | 18 | MMF added, target 2 g; CsA withdrawn over 6 wk | 35 wk | Slope 1/SCr 0.00585 ± 0.01122; 67% responders; Proteinuria 0.5 ± 0.55 g/24h | 0% | 100% | NA |
|  |  |  |  | 20 | MMF added, target 2 g; CsA continued |  | Slope 1/SCr -0.00728 ± 0.01105 (*P* = 0.0018); 25% responders (*P* = 0.021); Proteinuria 1.5 ± 0.48 g/24h (*P* = 0.01) | 0% | 85% | NA |
| McGrath *et al*[85] | Prospective, randomized, single-center | > 1-yr post transplant, BP-CAN, deteriorating renal function | CsA, azathioprine, prednisolone | 15 | MMF added, target 2 g; CsA withdrawn by 14 wk | 6 mo | SCr -58 μmol/L *vs* baseline (*P* < 0.001); isotope GFR + 8.5 mL/min *vs* baseline (*P* < 0.01) | 0% | NA | NA |
|  |  |  |  | 15 | CsA switch to TAC |  | SCr +15 μmol/L *vs* baseline (*P* = NS); isotope GFR - 2.1 mL/min *vs* baseline (*P* = NS) | 0% | NA | NA |
| Hanvesakul *et al*[86] | Retrospective, consecutive patients, single-center | > 1-yr post transplant, CAN | CsA or TAC, azathioprine, prednisolone | 30 | MMF added, target 1.5-2 g; azathioprine stopped; CNI withdrawn over 4 wk | 1 yr | eGFR + 2 mL/min *vs* baseline | 3.3% | 86.7% | 96.7% |
| Dudley *et al*[87] | Randomized, open, multicenter | > 6-mo post transplant, deteriorating renal function, no recent ACR | CsA monotherapy, or CsA/corticosteroid, or CsA/azathioprine/ corticosteroids | 73 | MMF added, target 2 g; azathioprine discontinued, if applicable; CsA withdrawn over 6 wk, if needed corticosteroid added | 1 yr | Response rate (6 mo): 58% stabilized or reduced SCr; Response rate (1 yr): 48%; Least squares mean SCr -24.9 μmol/L; Least squares mean CrCL +5 mL/min | 0% | 93.2% | 95.9% |
|  |  |  | CsA monotherapy, or CsA/corticosteroid, or CsA/azathioprine/ corticosteroids | 70 | Continued regimen |  | Response rate (6 mo): 32% stabilized or reduced SCr (*P* = 0.006); Response rate (1 yr): 35% (*P* = 0.1885); Least squares mean SCr +22.2 μmol/L (*P* < 0.01); Least squares mean CrCL  -0.7 mL/min (*P* < 0.01) | 0% | 94.3% | 100% |
| Weir *et al*[88] | Prospective, non-randomized, single-center | Mean 853.3 d post transplant, BP-CAN, deteriorating renal function, no ACR | CsA or TAC, prednisone, azathioprine or MMF | 18 | Azathioprine stopped; MMF added, target 2 g; CNI withdrawn | Mean 651 d | Response rate: 91.7% improved or lack of deterioration in renal function using least squares method slope 1/SCr (*P* = 0.038) | NCR | 100% | NA |
|  |  |  | CsA, prednisone, azathioprine or MMF | 67 | CsA dose reduced approximately 50%; azathioprine withdrawn; MMF added, target 2 g |  | Response rate: 51.7% improved or lack of deterioration | NCR | 100% | NA |
|  |  |  | TAC, prednisone, azathioprine or MMF | 33 | TAC dose reduced approximately 50%; azathioprine withdrawn; MMF added, target 2 g |  | 59.3% improved or lack of deterioration | NCR | 100% | NA |
| Weir *et al*[89] | Continuation of above trial |  |  | 13 | CNI withdrawn | 76 mo | 2.7 ± 0.2 mg/dL | 7.7% | 92.3% | 100% |
|  |  |  |  | 64 | CsA dose reduced | 54 mo | 3 ± 0.1 mg/dL | 4.7% | 62.5% | 92.2% |
|  |  |  |  | 28 | TAC dose reduced | 42 mo | 3 ± 0.2 mg/dL | 7.1% | 67.8% | 100% |
| Abramowicz *et al*[90] | Randomized, controlled, multicenter | No recent ACR, ≤ 1 ACR overall, 12 to 30 mo post-transplant, stable renal function | CsA, prednisone, ± azathioprine or MMF | 85 | MMF added over 3 mo, target 2 g; CsA withdrawn over 3 mo | 12 mo | CrCL improved 10% in 46%; SCr -1 μmol/L; CrCL +4.5 mL/min *vs* control group (*P* = 0.16), eGFR +2.3 mL/min *vs* control group (*P* = 0.24) | 10.6% | 100% | NA |
|  |  |  |  | 85 | MMF added over 3 mo, target 2 g; continued triple therapy |  | SCr +4 μmol/L | 2.4% (*P* = 0.03) | 100% |  |
| Abramowicz *et al*[91] | Continuation of above trial |  |  | 74 | CsA withdrawn | 60 mo | CrCL 67.4 mL/min | 10% | 88% | 93% |
|  |  |  |  | 77 | Triple therapy |  | CrCL 61.7 mL/min (*P* = 0.05) | 1% (*P* = 0.028) | 92% | 95% |
| Heeg *et al*[92] | Retrospective | BP-CNI toxicity, deteriorating renal function, mean 11.2 mo post-transplant | CsA or TAC, Prednisolone, ± MMF or MPS | 17 | MPS added; CNI withdrawn; MMF withdrawn | 48 mo | All *vs* Baseline. SCr at 6 mo -0.5 mg/dL (*P* < 0.05); eGFR at 6 mo +11 mL/min; SCr at 36 mo -0.5 mg/dL (*P* = 0.063); eGFR at 36 mo +11 mL/min *P* = 0.022); SCr at 48 mo +0.6 mg/dL (*P* = 0.27); eGFR at 48 mo +1 mL/min (*P* = 0.91) | NA | NA | NA |
| Mourer *et al*[93] | Prospective, randomized, single-center | No recent ACR, ≤ 2 ACR overall, at least 12 mo post-transplant, stable renal function | CsA or TAC, Prednisone, MMF | 79 | CNI withdrawn, MMF concentration controlled | 36 mo | eGFR 59.5 ± 2.1 mL/min | 5.1% | 98.7% | 94.9% |
|  |  |  |  | 79 | MMF withdrawn, CNI concentration controlled |  | eGFR 51.1 ± 2.1 mL/min (*P* = 0.006) | 2.5% | 98.7% | 92.4% |

ACR: Acute cellular rejection; BP-CAN: Biopsy-proven chronic allograft nephropathy; CAN: Chronic allograft nephropathy; CNI: Calcineurin inhibitor; CsA: Cyclosporine; eGFR: Estimated glomerular filtration rate; GFR: Glomerular filtration rate; MMF: Mycophenolate mofetil; MPS: Mycophenolate sodium; NA: not assessed/applicable; NCR: Not clearly reported by group; NS: Not significant; SCr: Serum creatinine; TAC: Tacrolimus.

**Table 2 Renal transplant studies utilizing sirolimus to withdraw calcineurin inhibitor beyond 6 mo post-transplant[102-118]**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Design | Population (N) | Baseline Regimen | N | Strategy | Follow-up | Renal function | Acute rejection | Graft survival | Patient survival |
| Gutierrez *et al*[102] | Cohort | > 1-yr post transplant, chronic allograft dysfunction, no proteinuria | Not specified | 8 | SRL added, CNI dose reduced 50% | 24.6 mo | Proteinuria = +0.56 g/d *vs* baseline (*P* = NS) | NA | 90.5% | 85.7% |
|  |  |  |  | 13 | SRL added, CNI withdrawn |  | Proteinuria = +0.67 g/d *vs* baseline (*P* = 0.02) |  |  |  |
|  |  | > 1-yr post transplant, chronic allograft dysfunction, proteinuria = 0.3-0.8 g/d |  | 10 | SRL added, CNI dose reduced 50% | 23.2 mo | Proteinuria = +0.5 g/d *vs* baseline (*P* = NS) | NA | 83.3% | 94.4% |
|  |  |  |  | 8 | SRL added, CNI withdrawn |  | Proteinuria = +1.1 g/d *vs* baseline (*P* = 0.05) |  |  |  |
|  |  | > 1-yr post transplant, chronic allograft dysfunction, proteinuria > 0.8 g/d |  | 14 | SRL added, CNI dose reduced 50% | 25.9 mo | Proteinuria = -0.1 g/d *vs* baseline (NS) | NA | 79.2% | 87.5% |
|  |  |  |  | 10 | SRL added, CNI withdrawn |  | Proteinuria = +2.3 g/d *vs* baseline (*P* = 0.01) |  |  |  |
| Maharaj *et al*[103] | Retrospective cohort | > 1-yr post transplant, CsA-induced biochemical toxicity | Not specified | 6 | SRL added, CNI withdrawn | 25 mo | Proteinuria = +0.06 g/d *vs* baseline  eGFR = +12.2 mL/min *vs* baseline | NA | NA | NA |
|  |  | > 1-yr post transplant, CAN |  | 6 |  |  | Proteinuria = +0.85 g/d *vs* baseline  eGFR = -9.7 mL/min *vs* baseline | NA | NA | NA |
|  |  | > 1-yr post transplant, Severe gum hypertrophy |  | 9 |  |  | Proteinuria = +0.99 g/d *vs* baseline  eGFR = -1.0 mL/min *vs* baseline | NA | NA | NA |
|  |  | 4.5 mo post transplant, Posttransplant diabetes |  | 4 |  |  | Proteinuria = -0.22 g/d *vs* baseline  eGFR = +13.3 mL/min *vs* baseline | NA | NA | NA |
|  |  | 5.5 mo post transplant, CNI induced histological nephrotoxicty |  | 2 |  |  | Proteinuria = +0.63 g/d *vs* baseline  eGFR = -10.0 mL/min *vs* baseline | NA | NA | NA |
|  |  | > 1-yr post transplant, CNI associated malignancy |  | 3 |  |  | Proteinuria = +0.09 g/d *vs* baseline  eGFR = +7.0 mL/min *vs* baseline | NA | NA | NA |
| Citterlo *et al*[104] | Cohort | > 6-mo post transplant, deteriorating renal function, sCr 2-4.5 mg/dL, proteinuria > 500 mg/d, biopsy confirmed fibrosis, tubular atropy and intimal hyperplasia | CsA or TAC or azathioprine with corticosteroid | 19 | SRL added to target trough 8-12 ng/mL, CNI withdrawn by 3 mo | 6 mo | Response rate: 57% improved or lacked deterioration in renal function | 0% | NA | 100% |
| Wu *et al*[105] | Retrospective cohort | > 1-yr post transplant, CAN | CsA or TAC/corticosteroids  or  CsA or TAC/corticosteroids/ MMF | 32 | SRL added with CNI dose reduced | 8.5 mo | Response rate: 50% improved or lacked deterioration in renal function | 3.1% | 87.5% | NA |
| Chhabra *et al*[106] | Randomized, prospective, open-label, single-center | > 1-yr post transplant | TAC, MMF | 123 | SRL added to target trough 5-8 ng/mL, TAC withdrawn by week 2 | 41.1 mo | eGFR = -3.3 mL/min per 1.73m3 *vs* baseline  proteinuria > 1 g/d = + 4.7% *vs* baseline | 5.7%  (ACR)  4.1% (AHR) | 97.6% | 97% |
|  |  |  |  | 64 | Continue TAC to target trough 6-8 ng/mL | 40.7 mo | eGFR = -8.7 mL/min per 1.73m3 *vs* baseline, proteinuria > 1 g/d = + 7.4% *vs* baseline | 6.4%  (ACR)  3.1% (AHR) | 97% | 100% |
| Wali *et al*[107] | Cohort | Renal dysfunction and biopsy confirmed CAN | TAC/MMF  or  TAC/MMF/corticosteroids | 159 | SRL added, target trough 8-10 ng/mL, TAC withdrawn after second dose of SRL | 24 mo | sCr = -1.1 mg/dL *vs* baseline (*P* < 0.0001)  eGFR = +21 mg/dL *vs* baseline (*P* < 0.0001) | 9.6% | 65% | 90% |
| Diekmann *et al*[108] | Cohort | > 1-yr post transplant, biopsy confirmed CNI toxicity | CsA or TAC/corticosteroids,  or  CsA or TAC/corticosteroids/ azathioprine,  or  CsA or TAC/corticosteroids/ MMF,  or  CsA or TAC/MMF,  or  CsA or TAC/azathioprine | 22 | SRL added, target trough 8-12 ng/mL, CsA or TAC reduced by 50% immediately then further reduced 10%-20% weekly | 6 mo | sCr = -0.7 mg/dL *vs* baseline (%= NS), Response rate: 59.1% improved or lacked deterioration in renal function | NA | 86% | 100% |
| Bumbea *et al*[109] | Prospective, single-center cohort | >6-mo post transplant, chronic allograft dysfunction or recurrent cutaneous cancer | CsA or TAC/corticosteroids,  or  CsA or TAC/corticosteroids/ azathioprine  or  CsA or TAC/corticosteroids/ MMF | 43 | SRL added, target trough = 8-12 ng/mL, CNI withdrawn abruptly or by week 3 | 27 mo | sCr = -17.8 µmol/L *vs* baseline  (*P* = NS)  CrCL = +2.3 ml/min *vs* baseline (*P* = NS)  Proteinuria (> 1g/d): 20.6% at 2 yr (*P* = 0.01) | 0% | 93% | 95.3% |
| Boratynska *et al*[110] | Cohort | > 1-yr post transplant, biopsy confirmed CAN | CsA, prednisone, azathioprine | 5 | SRL added, target trough 10-18 ng/mL, CsA withdrawn immediately. After 5 mo, SRL withdrawn and CsA reinitiated | 3 mo | sCr = +1.6 mg/dL and proteinuria = +461 mg/dL after 3 mo SRL *vs* baseline  sCr = +1.1 mg/dL and proteinuria = +6 mg/dL 6 mo after reconversion to CsA *vs* baseline  sCr = -0.5 mg/dL and proteinuria = -455 mg/dL after reconversion to CsA *vs* SRL | 0% | 40% | 100% |
| Martínez-Mier *et al*[111] | Retrospective cohort | > 6-mo post transplant, > 20% sCr increase in 6 mo or sCr 2-4.5 mg/dL | CsA, prednisone, MMF | 15 | SRL added, target trough 8-12 ng/mL, CsA withdrawn immediately | 6 mo | sCr = -0.78 mg/dL *vs* baseline (*P* = 0.003)  BUN = - 9.84 mg/dL *vs* baseline (*P* = NS) | 0% | 100% | 100% |
| Kamar *et al*[112] | Prospective, multicenter, noncomparative, open-label cohort | > 1-yr post transplant, moderate renal insufficiency, sCr 160-265 µmol/L | CsA or TAC, corticosteroids, MMF | 44 | SRL added to target trough 6-10 ng/mL, CNI withdrawn | 6 mo | GFR = +7.09 ml/min *vs* baseline (*P* = 0.03)  Proteinuria = + 0.57 g/d | 2.3% | 100% | 100% |
| Chen *et al*[113] | Cohort | > 6-mo post transplant, biopsy confirmed CAN | CsA or TAC, prednisone, MMF | 16 | SRL added, target trough 5-8 ng/mL, CNI withdrawn | 12 mo | Response rate: 43.8% improved or lacked deterioration in renal function | 0% | 88% | 100% |
| Stallone *et al*[114] | Prospective, open-label, single-center | > 1-yr post transplant,  Scr 1-3 mg/dL | CsA or TAC, corticosteroids, MMF | 50 | 40% CNI dose reduction | 24 mo | sCr= -0.02 mg/dL *vs* baseline (*P* = NS)  CrCL -3.0 mL/min *vs* baseline (*P* = NS)  Proteinuria = +0.17 *vs* baseline (*P* = NS)  Follow-up biopsy: worsened CAN score, increased α-SMA | 0% | 84% | 100% |
|  |  |  |  | 34 | SRL added, CNI immediately withdrawn |  | sCr = -0.14 mg/dL *vs* baseline (*P* = NS)  CrCL = +3.0 mg/dL *vs* baseline (*P* = NS)  Proteinuria = +0.37 g/d *vs* baseline (*P* = NS)  Follow-up biopsy: stable CAN score, improved α-SMA | 0% | 97% (*P* = 0.04) | 100% |
| Paoletti *et al*[115] | Cohort | > 6-mo post transplant, biopsy confirmed renal allograft dysfunction | CsA or TAC, corticosteroids, MMF | 13 | SRL added, target trough 4-8 ng/mL, CNI withdrawn | 3 yr | sCr = -0.3 mg/dL *vs* baseline (*P* = 0.016)  eGFR = +5.5 mg/dL *vs* baseline (*P* = 0.011)  Proteinuria = +0.21 g/d *vs* baseline (*P* = 0.83) | 8% | 100% | 100% |
|  |  | > 6-mo post transplant with stable graft function |  | 26 | Continued regimen |  | sCr= +0.3 mg/dL *vs* baseline (*P* = 0.016)  eGFR = -6.4 mg/dL *vs* baseline (*P* = 0.011)  Proteinuria = +0.17 g/d *vs* baseline (*P* = 0.83) | 4% | 96% | 96% |
| Alarrayed *et al*[116] | Retrospective, Observational, single-center | > 1-yr post transplant, sCr < 140 µmol/L | CsA or TAC, corticosteroids, azathioprine or MMF | 45 | SRL added to target trough 5-8 ng/mL, CNI withdrawn immediately | 72.8 mo | sCr = -6 µmol/L *vs* baseline (*P* = 0.001)  Proteinuria = +0.2 g/d *vs* baseline (*P* = NS) | 0% | 100% | NA |
|  |  | > 1-yr post transplant, sCr ≥ 140 µmol/L |  | 19 |  |  | sCr = -13 µmol/L *vs* baseline (*P* = 0.01)  Proteinuria = +0.6 g/d *vs* baseline (*P* = 0.001) | 36.4% | 72.7% | NA |
| Fischereder *et al*[117] | Prospective cohort | > 1-yr post transplant, deteriorating renal function, Scr 1.8-4 mg/dL | CsA or TAC, corticosteroids, azathioprine or MMF | 12 | SRL added, target trough = 10-20 ng/mL, CNI withheld by 4 wk | 12 mo | sCr = -0.3 mg/dL vs. baseline (*P* = 0.198)  CrCL = +5.8 mL/min (*P* = 0.0368) Proteinuria = +735 mg/g creatinine *vs* baseline (*P* = 0.13) | 0% | 100% | 100% |
| Schena *et al*[118] | Randomized, prospective, open-label, multicenter, blinded, comparative trial | > 6-mo post transplant, baseline GFR > 40 mL/min | CsA or TAC, corticosteroids, azathioprine or MMF | 497 | SRL added, target trough 8-20 ng/mL, CNI withdrawn in 1 d, MMF or azathioprine dose reduced or withdrawn | 24 mo | GFR = + 1.3 mL/min in patients converted to SRL as compared with patients continued on CNI at 12 mo (*P* = NS)  GFR = +1.3 mL/min *vs* baseline, UPr/Cr = -84 *vs* baseline | 7.8% | 92.4% | 95.6% |
|  |  | > 6-mo post transplant, baseline GFR 20-40 mL/min |  | 58 |  |  | GFR = + 3.8 mL/min in patients converted to SRL as compared with patients continued on CNI at 24 mo (*P* = NS) | 8.6% | 65.5% | 82.8% |
|  |  | > 6-mo post transplant, baseline GFR > 40 mL/min |  | 246 | Continue regimen |  | GFR = -1.8 mL/min *vs* baseline, UPr/Cr = -31 *vs* baseline | 6.5% | 93.9% | 96.3% |
|  |  | > 6-mo post transplant, baseline GFR 20-40 mL/min |  | 29 |  |  | GFR = + 2.6 mL/min in patients continued on CNI as compared with patients converted to SRL at 12 mo (*P* = NS) | 10.3% | 62.1% | 89.7% |

α-SMA: Α-smooth muscle actin; AHR: Acute humoral rejection; CAN: Chronic allograft nephropathy; CNI: Calcineurin inhibitor; CsA: Cyclosporine; GFR: Glomerular filtration rate; MMF: Mycophenolate mofetil; NS: Not significant; SCr: Serum creatinine; TAC: Tacrolimus.

**Table 3 Renal transplant studies utilizing everolimus to withdraw calcineurin inhibitor beyond 6 mo post-transplant[126-135]**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Design | Population (N) | Baseline regimen | N | Strategy | Follow-up | Renal function | Acute rejection | Graft survival | Patient survival |
| Giron *et al*[126] | Case Series | Conversion due to unspecified reasons in Hispanic renal transplant patients (15 from cadaveric donors), mean conversion 8 mo post-transplant | CsA or TAC, and unspecified regimen | 21 | Everolimus added with MPS of MMF with complete suspension of CNI | 10 mo (range, 2 to 22) | Mean SCr showed a trend to decline: preconversion 1.7 mg/dL; postconversion 1.5 mg/dL | 17% | 100% | 100% |
| Sánchez Fructuoso *et al*[127] | Case series,  Prospective, open | CAN or other reasons, stable renal function, mean 77 mo post-transplant | CNI and unspecified regimen | 78 | Switched to everolimus with complete and quick elimination of the CNI: An initial dose of 3 mg/d was adequate to obtain the recommended trough levels between 5 and 10 ng/mL | 12 mo | Baseline CrCL = 51.9 ± 2.7 ml/min, and 3 mo = 55.7 ± 3.2 (*P* = 0.02). 12-mo CrCL not stated. Proteinuria = increased at 3 mo (*P* < 0.001), decreased between 3 to 6 mo (*P* = 0.001), but remained higher than basal levels (*P* = 0.002). Everolimus stopped in 13 patients (16.7%) | NA | NA | NA |
| Ruiz *et al*[128] | Case Series | CAN with deteriorating renal function | CsA or TAC, and unspecified regimen; tripe drug (41%), double-drug (52%), monotherapy (7%) | 32 | Everolimus added, to eliminate CNI | 6 mo | Baseline SCr 1.93 ± 0.13 mg/dL *vs* 1.86 ± 0.14, *P* = 0.07. Proteinuria = 1.62 ± 0.62 g/d *vs* 2.11 ± 0.73 (*P* = 0.11) | NA | NA | NA |
| Fernández *et al*[129] | Case series | Cadaveric renal transplant patients with CAN, at a mean 123.8 ± 74.2 mo post-transplant | CsA or TAC, ± MMF or azathioprine, corticosteroid not specified | 17 | Converted to everolimus with complete suspension of CNI | 24 mo | Baseline SCr of 1.8 ± 0.4; after a year, 1.62 ± 0.49; and after 2 yr, 1.56 ± 0.49 mg/dL (*P* < 0.05). Proteinuria was baseline 0.30 ± 0.13 mg/mg, 1 yr = 0.63 ± 0.68 (*P* < 0.05), and 2 yr = 0.48 ± 0.34. Protein/creatinine quotient was: baseline 0.30 ± 0.13; one year 0.63 ± 0.68; and 2 yr 0.48 ± 0.34. CrCL was baseline 37.1 ± 11.14 ml/min and 2 yr = 46.6 ± 14.6 (*P* < 0.05) | NA | NA | 100% |
|  |  | Cadaveric renal transplant patients treated with non-CAN diagnosis at a mean 123.8 ± 74.2 mo post-transplant | CsA or TAC, ± MMF or azathioprine, corticosteroid not specified | 10 | Converted to everolimus with complete suspension of CNI | 24 mo | Baseline SCr of 1.1 ± 0.32 mg/dL; , 1 yr 0.97 ± 0.15, and 2 yr 0.97 ± 0.15. Proteinuria at baseline 0.12 ± 0.07 mg/mg, 1 yr = 0.46 ± 0.68 (*P* < 0.05), and 2 years = 0.32 ± 0.17 (*P* < 0.05). Protein/creatinine quotient was: baseline 0.2 ± 0.07, 1 yr = 0.73 ± 0.7, and 2 yr = 0.32 ± 0.17. CrCL was baseline 68.81 ± 19 ml/min and 2 yr 74.56 ± 12.3 | NA | NA | 50%, due to tumors |
| Kamar *et al*[130] | Retrospective case-control | DSA-free kidney transplant patients with CNI toxicity, CAN or other diagnosis | CsA or TAC or belatacept, ± MPA or azathioprine, ± corticosteroids | 61 | Converted to everolimus-based regimen without CNIs | 36 ± 25 mo | SCr (μM) baseline 135 ± 37 to 141 ± 54 (*P* = NS). aMDRD GFR (mL/min) 54 ± 18 to 56 ± 22 (*P* = NS) | NA | NA | NA |
|  |  |  | CsA or TAC, ± MPA or azathioprine, ± corticosteroids | 61 | Matched control patients on CNI |  | SCr (μM) baseline 133 ± 51 to 131 ± 45 (*P* = NS). aMDRD GFR (mL/min) 65.7 ± 25 to 62 ± 24 (*P* = NS) |  |  |  |
| Morales *et al*[131] | Case series | 1st or 2nd transplant, converted due to CAN, nephrotoxicty or malignancy, mean 5 yr post-transplant | CsA or TAC, ± MMF or azathioprine, ± corticosteroid | 8 | Everolimus added to replace (*n* = 6) or decrease (30% reduction) CNI dose (*n* = 2). Antiproliferative dose reduced. | 1-16 mo | Mean baseline SCr was 1.96 ± 0.69 mg/dL *vs* 1.59±0.52. Mean CrCL = 51 ± 34.6 mL/min *vs* 56.5 ± 25.5. Mean Proteinuria :creatinine ratio = 1.34 ± 2.17 *vs* 1.28 ± 1.19 mg/g. | NA | NA | NA |
| Holdaas *et al*[132] | Prospective, randomized, open-label, multi-center. ASCERTAIN study | > 6-mopost transplant, renal impairment, no recent ACR < 3 mo | CsA or TAC, ± MPA or azathioprine, ± corticosteroids | 127 | Everolimus added, target 8-12 ng/mL; to eliminate CNI | 24 mo | Mean measured GFR at month 24, 48 ± 22 mL/min per 1.73m2 Difference versus control was 1.12 mL/min per 1.73 m, 95%CI (-3.51 to 5.76) (*P* = 0.63). Urine protein: creatinine (mg/mmol) median increased from baseline 16.6 (3.5-413.7) to 32.6 (4.1-665.9; *P* = 0.007 *vs* control) | 5.5% | 94.5% | 97.6% |
|  |  |  |  | 144 | Everolimus added, target 3-8 ng/mL; to decrease CNI dose |  | Mean measured GFR at month 24, 46.6 ± 21.1 mL/min per 1.73 m2. Difference *vs* control was 0.59 mL/min per 1.73 m, 95%CI (-3.88 to 5.07) (*P* = 0.79). Urine protein: creatinine (mg/mmol) median increased from baseline 13.5 (2.4-319.4) to 22.4 (5.1-513.5; *P* = 0.54 *vs* control) | 5.6% | 92.4% | 97.9% |
|  |  |  |  | 123 | Controls maintained current CNI-based regimen |  | Mean measure GFR at month 24 46 ± 20.4 mL/min. Urine protein:creatinine (mg/mmol) median remained stable from baseline 14.3 (3.3-431.9) to 19.3 (3.3-431.9) | 2.4% | 95.1% | 100% |
| Inza *et al*[133] | Case series | Cadaveric kidney allograft, SCr > 2 mg/dL, proteinuria < 1 g/ 24h | CsA or TAC, ± MPA or sirolimus, corticosteroids | 22 | Switched CNI to Everolimus, mean starting dose 1.4 mg/d. | 24 mo | Baseline CrCL 29.31 ± 10.15 mL/min to 3-mo 37.99 ± 14.44 (*P* = 0.0076). No results specified for 24 mo, but authors stated CrCL trended to decline (*P* = 0.6). Proteinuria (mg/24h) increased from baseline 384 ± 26.13 to one month, 958 ± 1019.38 (*P* = 0.05), to month 12, 1295 ± 1200.83 (*P* = 0.0106) | 4.5% | 90.5% | 100% |
| Cataneo-Dávila *et al*[134] | Prospective, randomized, open pilot | > 6-mo post transplant, stable renal function, Banff grade I or II CAN within 6 mo, without ACR or grade III CAN in last 3 mo | CsA or TAC, MMF or azathioprine, corticosteroids | 10 | MMF or azathioprine were withdrawn and Everolimus added to decrease CNI dose by 80%. | 12 mo | Baseline and end-of-study data were as follows: SCr, 1.27 ± 0.35 mg/dL *vs* 1.24 ± 0.4 mg/dL; estimated GFR = 72.4 ± 19.86 mL/min *vs* 76.26 ± 22.69 mL/min (*P* = NS); microalbuminuria 0 mg/g (range 0-50) *vs* 0 (range 0-609; *P* = NS) | 10% | NA | NA |
|  |  |  | CsA or TAC, MMF or azathioprine, corticosteroids | 10 | Everolimus added to eliminate CNI gradually. MMF or azathioprine withdrawn, then re-introduced at CNI elimination |  | Baseline and end-of-study data were as follows: SCr 1.27 ± 0.36 mg/dL *vs* 1.25 ± 0.3 mg/dL; estimated GFR 66.2 ± 12.95 mL/min *vs* 66.2 ± 13.73 mL/min (*P* = NS); microalbuminuria 0 mg/g (range 0-60) *vs* 0 (range 0-34; *P* = NS) | 0 | NA | NA |
| Albano *et al*[135] | Prospective, randomized, open-label, multi-center. FOREVER trial | Completion of CALLISTO study of patients at risk for DGF, from transplantation to month 12, with proteinuria < 1 g/24h at month 12 | Low-exposure CsA, everolimus, corticosteroids | 15 | Switch CsA to mycophenolate sodium 720 mg/d, increase everolimus, target trough goal 6-10 ng/mL | 12 mo | Median (range) mGFR was 54 (21-87) mL/min at baseline (*P* = 0.053 *vs* CNI at baseline) *vs* 56 (18-126) mL/min at month 12 (*P* = 0.007 *vs* CNI continuation; *P* = 0.3 *vs* baseline). Difference in mGFR (SE) was +10.3 ml/min (4.8) *vs* baseline. SCr (SE) = 24 µmol/ml (27). Proteinuria least squares mean change from baseline (SE) = 0.16 g/24h (0.2). | 0 | 100 | 100 |
|  |  |  |  | 15 | Continue CsA and everolimus unchanged, trough goal 3-8 ng/mL |  | Median (range) mGFR was 37 (range 18-69) mL/min at baseline (*P* = 0.053) *vs* 32 (12-63) mL/min at month 12 (*P* = 0.007). Difference in mGFR (SE) was -4.1 mL/min (5) *vs* baseline. Proteinuria least squares mean change from baseline (SE) = 0.08 g/24h (0.23). | 6.67% | 100 | 93.3 |

ACR: Acute cellular rejection; aMDRD: Abbreviated modified diet in renal disease; BP-CAN: Biopsy-proven chronic allograft nephropathy; CAN: Chronic allograft nephropathy; CNI: Calcineurin inhibitor; CsA: Cyclosporine; DGF: Delayed graft function; DSA: Donor specific antibody; eGFR: Estimated glomerular filtration rate; GFR: Glomerular filtration rate; MMF: Mycophenolate mofetil; MPA: Mycophenolic acid (includes MMF and MPS); MPS: Mycophenolate sodium; NA: Not assessed/applicable; NCR: Not clearly reported by group; NS: Not significant; SCr: Serum creatinine; TAC: Tacrolimus.